BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol 2011;8:292-301. [PMID: 21386818 DOI: 10.1038/nrclinonc.2011.30] [Cited by in Crossref: 293] [Cited by in F6Publishing: 302] [Article Influence: 26.6] [Reference Citation Analysis]
Number Citing Articles
1 Toffanin S, Sia D, Villanueva A. microRNAs: new ways to block tumor angiogenesis? J Hepatol 2012;57:490-1. [PMID: 22691573 DOI: 10.1016/j.jhep.2012.06.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
2 Goto K, Roca Suarez AA, Wrensch F, Baumert TF, Lupberger J. Hepatitis C Virus and Hepatocellular Carcinoma: When the Host Loses Its Grip. Int J Mol Sci. 2020;21. [PMID: 32357520 DOI: 10.3390/ijms21093057] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
3 Machoń-Grecka A, Dobrakowski M, Boroń M, Lisowska G, Kasperczyk A, Kasperczyk S. The influence of occupational chronic lead exposure on the levels of selected pro-inflammatory cytokines and angiogenic factors. Hum Exp Toxicol 2017;36:467-73. [PMID: 28395533 DOI: 10.1177/0960327117703688] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
4 Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? Angiogenesis. 2017;20:185-204. [PMID: 28361267 DOI: 10.1007/s10456-017-9552-y] [Cited by in Crossref: 215] [Cited by in F6Publishing: 220] [Article Influence: 43.0] [Reference Citation Analysis]
5 Wang G, Wu B, Li Q, Chen S, Jin X, Liu Y, Zhou Z, Shen Y, Huang P. Active Transportation of Liposome Enhances Tumor Accumulation, Penetration, and Therapeutic Efficacy. Small 2020;16:e2004172. [PMID: 33030305 DOI: 10.1002/smll.202004172] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
6 Ch’ang HJ. Optimal combination of antiangiogenic therapy for hepatocellular carcinoma. World J Hepatol 2015; 7(16): 2029-2040 [PMID: 26261692 DOI: 10.4254/wjh.v7.i16.2029] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
7 Zhu AX, Finn RS, Mulcahy M, Gurtler J, Sun W, Schwartz JD, Dalal RP, Joshi A, Hozak RR, Xu Y, Ancukiewicz M, Jain RK, Nugent FW, Duda DG, Stuart K. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res. 2013;19:6614-6623. [PMID: 24088738 DOI: 10.1158/1078-0432.ccr-13-1442] [Cited by in Crossref: 99] [Cited by in F6Publishing: 51] [Article Influence: 11.0] [Reference Citation Analysis]
8 Ma X, Qin X, Shang X, Liu M, Wang X. Organic anion transport polypeptide 1b2 selectively affects the pharmacokinetic interaction between paclitaxel and sorafenib in rats. Biochemical Pharmacology 2019;169:113612. [DOI: 10.1016/j.bcp.2019.08.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
9 Shang F, Liu M, Li B, Zhang X, Sheng Y, Liu S, Han J, Li H, Xiu R. The anti-angiogenic effect of dexamethasone in a murine hepatocellular carcinoma model by augmentation of gluconeogenesis pathway in malignant cells. Cancer Chemother Pharmacol 2016;77:1087-96. [PMID: 27071921 DOI: 10.1007/s00280-016-3030-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
10 van Breugel JMM, Geschwind JF, Mirpour S, Savic LJ, Zhang X, Duran R, Lin M, Miszczuk M, Liapi E, Chapiro J. Theranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model. Theranostics 2019;9:3674-86. [PMID: 31281506 DOI: 10.7150/thno.32943] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
11 Liu M, Jiang L, Guan XY. The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update. Protein Cell 2014;5:673-91. [PMID: 24916440 DOI: 10.1007/s13238-014-0065-9] [Cited by in Crossref: 80] [Cited by in F6Publishing: 87] [Article Influence: 10.0] [Reference Citation Analysis]
12 Li Q, Liu Z, Xu M, Xue Y, Yao B, Dou C, Jia Y, Wang Y, Tu K, Zheng X, Yao Y. PCAF inhibits hepatocellular carcinoma metastasis by inhibition of epithelial-mesenchymal transition by targeting Gli-1. Cancer Lett 2016;375:190-8. [PMID: 26945969 DOI: 10.1016/j.canlet.2016.02.053] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
13 Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M; REACH Trial Investigators. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2015;16:859-70. [PMID: 26095784 DOI: 10.1016/S1470-2045(15)00050-9] [Cited by in Crossref: 419] [Cited by in F6Publishing: 246] [Article Influence: 59.9] [Reference Citation Analysis]
14 Kantarci M, Pirimoglu B. Radiological Response to the Locoregional Treatment in Hepatocellular Carcinoma: RECIST, mRECIST, and Others. J Gastrointest Cancer. 2017;48:282-285. [PMID: 28624974 DOI: 10.1007/s12029-017-9969-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
15 Zhang Q, Lin Z, Yin X, Tang L, Luo H, Li H, Zhang Y, Luo W. In vitro and in vivo study of hydralazine, a potential anti-angiogenic agent. European Journal of Pharmacology 2016;779:138-46. [DOI: 10.1016/j.ejphar.2016.03.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
16 Alqahtani SA, Colombo M. Multikinase inhibitors to treat hepatocellular carcinoma failures to sorafenib-time has come for a better approach. Ann Transl Med 2020;8:1255. [PMID: 33178787 DOI: 10.21037/atm-2020-79] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Schoenberg MB, Hao J, Bucher JN, Miksch RC, Anger HJW, Mayer B, Mayerle J, Neumann J, Guba MO, Werner J, Bazhin AV. Perivascular Tumor-Infiltrating Leukocyte Scoring for Prognosis of Resected Hepatocellular Carcinoma Patients. Cancers (Basel) 2018;10:E389. [PMID: 30340430 DOI: 10.3390/cancers10100389] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
18 Takaya H, Namisaki T, Kitade M, Kaji K, Nakanishi K, Tsuji Y, Shimozato N, Moriya K, Seki K, Sawada Y, Saikawa S, Sato S, Kawaratani H, Akahane T, Noguchi R, Matsumoto M, Yoshiji H. VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma. BMC Gastroenterol. 2019;19:167. [PMID: 31638892 DOI: 10.1186/s12876-019-1082-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
19 Masuda C, Yanagisawa M, Yorozu K, Kurasawa M, Furugaki K, Ishikura N, Iwai T, Sugimoto M, Yamamoto K. Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model. Int J Oncol 2017;51:425-34. [PMID: 28627678 DOI: 10.3892/ijo.2017.4036] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
20 Hayano K, Lee SH, Sahani DV. Imaging for assessment of treatment response in hepatocellular carcinoma: Current update. Indian J Radiol Imaging 2015;25:121-8. [PMID: 25969635 DOI: 10.4103/0971-3026.155835] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
21 Muramatsu S, Tanaka S, Mogushi K, Adikrisna R, Aihara A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N, Nakayama K, Tanaka H, Yamaoka S, Arii S. Visualization of stem cell features in human hepatocellular carcinoma reveals in vivo significance of tumor-host interaction and clinical course. Hepatology. 2013;58:218-228. [PMID: 23447025 DOI: 10.1002/hep.26345] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
22 Chiew GGY, Wei N, Sultania S, Lim S, Luo KQ. Bioengineered three-dimensional co-culture of cancer cells and endothelial cells: A model system for dual analysis of tumor growth and angiogenesis. Biotechnol Bioeng 2017;114:1865-77. [PMID: 28369747 DOI: 10.1002/bit.26297] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
23 Bertino G, Di Carlo I, Ardiri A, Calvagno GS, Demma S, Malaguarnera G, Bertino N, Malaguarnera M, Toro A, Malaguarnera M. Systemic therapies in hepatocellular carcinoma: present and future. Future Oncol. 2013;9:1533-1548. [PMID: 24106903 DOI: 10.2217/fon.13.171] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
24 Zhu AX. New agents on the horizon in hepatocellular carcinoma. Ther Adv Med Oncol. 2013;5:41-50. [PMID: 23323146 DOI: 10.1177/1758834012458480] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
25 Li H. Angiogenesis in the progression from liver fibrosis to cirrhosis and hepatocelluar carcinoma. Expert Rev Gastroenterol Hepatol 2021;15:217-33. [PMID: 33131349 DOI: 10.1080/17474124.2021.1842732] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Park M, Kim N, Kang C, Oh C, Kim G. Antimetastatic Effects of Gambogic Acid are Mediated via the Actin Cytoskeleton and NF-κB Pathways in SK-HEP1 Cells: Antimetastatic Effects of Ga. Drug Dev Res 2015;76:132-42. [DOI: 10.1002/ddr.21249] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
27 Chen C, Lou T. Hypoxia inducible factors in hepatocellular carcinoma. Oncotarget 2017;8:46691-703. [PMID: 28493839 DOI: 10.18632/oncotarget.17358] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 15.5] [Reference Citation Analysis]
28 Blechacz B, Mishra L. Hepatocellular carcinoma biology. Recent Results Cancer Res. 2013;190:1-20. [PMID: 22941010 DOI: 10.1007/978-3-642-16037-0_1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
29 Villani R, Vendemiale G, Serviddio G. Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy. Int J Mol Sci 2018;20:E49. [PMID: 30583555 DOI: 10.3390/ijms20010049] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
30 Chen Y, Liu YC, Sung YC, Ramjiawan RR, Lin TT, Chang CC, Jeng KS, Chang CF, Liu CH, Gao DY, Hsu FF, Duyverman AM, Kitahara S, Huang P, Dima S, Popescu I, Flaherty KT, Zhu AX, Bardeesy N, Jain RK, Benes CH, Duda DG. Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. Sci Rep 2017;7:44123. [PMID: 28276530 DOI: 10.1038/srep44123] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
31 Lu L, Wei W, Huang C, Li S, Zhong C, Wang J, Yu W, Zhang Y, Chen M, Ling Y, Guo R. A new horizon in risk stratification of hepatocellular carcinoma by integrating vessels that encapsulate tumor clusters and microvascular invasion. Hepatol Int 2021;15:651-62. [PMID: 33835379 DOI: 10.1007/s12072-021-10183-w] [Reference Citation Analysis]
32 Ng KT, Guo DY, Cheng Q, Geng W, Ling CC, Li CX, Liu XB, Ma YY, Lo CM, Poon RT, Fan ST, Man K. A garlic derivative, S-allylcysteine (SAC), suppresses proliferation and metastasis of hepatocellular carcinoma. PLoS One 2012;7:e31655. [PMID: 22389672 DOI: 10.1371/journal.pone.0031655] [Cited by in Crossref: 60] [Cited by in F6Publishing: 48] [Article Influence: 6.0] [Reference Citation Analysis]
33 Shih T, Tien Y, Wen C, Yeh T, Yu M, Huang C, Lee Y, Yen T, Hsieh S. MicroRNA-214 downregulation contributes to tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma. Journal of Hepatology 2012;57:584-91. [DOI: 10.1016/j.jhep.2012.04.031] [Cited by in Crossref: 137] [Cited by in F6Publishing: 126] [Article Influence: 13.7] [Reference Citation Analysis]
34 Watanabe H, Hayano K, Ohira G, Imanishi S, Hanaoka T, Hirata A, Kano M, Matsubara H. Quantification of Structural Heterogeneity Using Fractal Analysis of Contrast-Enhanced CT Image to Predict Survival in Gastric Cancer Patients. Dig Dis Sci 2021;66:2069-74. [PMID: 32691383 DOI: 10.1007/s10620-020-06479-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Ding XX, Zhu QG, Zhang SM, Guan L, Li T, Zhang L, Wang SY, Ren WL, Chen XM, Zhao J, Lin S, Liu ZZ, Bai YX, He B, Zhang HQ. Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy. Oncotarget. 2017;8:55715-55730. [PMID: 28903454 DOI: 10.18632/oncotarget.18382] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 8.2] [Reference Citation Analysis]
36 Yang C, Qin S. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma. Cancer Med. 2018;7:4570-4583. [PMID: 30109780 DOI: 10.1002/cam4.1664] [Cited by in Crossref: 18] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
37 Li M, Yu X, Li W, Liu T, Deng G, Liu W, Liu H, Gao F. Deguelin suppresses angiogenesis in human hepatocellular carcinoma by targeting HGF-c-Met pathway. Oncotarget 2018;9:152-66. [PMID: 29416603 DOI: 10.18632/oncotarget.22077] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
38 Buijs N, Oosterink JE, Jessup M, Schierbeek H, Stolz DB, Houdijk AP, Geller DA, van Leeuwen PA. A new key player in VEGF-dependent angiogenesis in human hepatocellular carcinoma: dimethylarginine dimethylaminohydrolase 1. Angiogenesis 2017;20:557-65. [PMID: 28741166 DOI: 10.1007/s10456-017-9567-4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 7.6] [Reference Citation Analysis]
39 Ku CY, Wang YR, Lin HY, Lu SC, Lin JY. Corosolic Acid Inhibits Hepatocellular Carcinoma Cell Migration by Targeting the VEGFR2/Src/FAK Pathway. PLoS One 2015;10:e0126725. [PMID: 25978354 DOI: 10.1371/journal.pone.0126725] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
40 Li M, Li J, Guo X, Pan H, Zhou Q. Absence of HTATIP2 Expression in A549 Lung Adenocarcinoma Cells Promotes Tumor Plasticity in Response to Hypoxic Stress. Cancers (Basel) 2020;12:E1538. [PMID: 32545251 DOI: 10.3390/cancers12061538] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Li G, Zhang H, Wan X, Yang X, Zhu C, Wang A, He L, Miao R, Chen S, Zhao H. Long noncoding RNA plays a key role in metastasis and prognosis of hepatocellular carcinoma. Biomed Res Int. 2014;2014:780521. [PMID: 24757675 DOI: 10.1155/2014/780521] [Cited by in Crossref: 25] [Cited by in F6Publishing: 59] [Article Influence: 3.1] [Reference Citation Analysis]
42 Dai L, Peng XX, Tan EM, Zhang JY. Tumor-associated antigen CAPERα and microvessel density in hepatocellular carcinoma. Oncotarget 2016;7:16985-95. [PMID: 26934653 DOI: 10.18632/oncotarget.7707] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
43 Simone V, Brunetti O, Lupo L, Testini M, Maiorano E, Simone M, Longo V, Rolfo C, Peeters M, Scarpa A, Azzariti A, Russo A, Ribatti D, Silvestris N. Targeting Angiogenesis in Biliary Tract Cancers: An Open Option. Int J Mol Sci 2017;18:E418. [PMID: 28212293 DOI: 10.3390/ijms18020418] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
44 Ruan Q, Wang H, Burke LJ, Bridle KR, Li X, Zhao CX, Crawford DHG, Roberts MS, Liang X. Therapeutic modulators of hepatic stellate cells for hepatocellular carcinoma. Int J Cancer 2020;147:1519-27. [PMID: 32010970 DOI: 10.1002/ijc.32899] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
45 Duda DG. Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer. ISRN Cell Biol 2012;2012:587259. [PMID: 24340224 DOI: 10.5402/2012/587259] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
46 Jiang H, Wu D, Xu D, Yu H, Zhao Z, Ma D, Jin J. Eupafolin Exhibits Potent Anti-Angiogenic and Antitumor Activity in Hepatocellular Carcinoma. Int J Biol Sci 2017;13:701-11. [PMID: 28655996 DOI: 10.7150/ijbs.17534] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
47 Lei D, Chen Y, Zhou Y, Hu G, Luo F. An angiogenesis-related long noncoding RNA signature correlates with prognosis in patients with hepatocellular carcinoma. Biosci Rep 2021;41:BSR20204442. [PMID: 33764367 DOI: 10.1042/BSR20204442] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Goyal L, Zheng H, Abrams TA, Miksad R, Bullock AJ, Allen JN, Yurgelun MB, Clark JW, Kambadakone A, Muzikansky A, Knowles M, Galway A, Afflitto AJ, Dinicola CF, Regan E, Hato T, Mamessier E, Shigeta K, Jain RK, Duda DG, Zhu AX. A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res 2019;25:80-9. [PMID: 30190369 DOI: 10.1158/1078-0432.CCR-18-0847] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
49 Wu TC, Shen YC, Cheng AL. Evolution of systemic treatment for advanced hepatocellular carcinoma. Kaohsiung J Med Sci 2021;37:643-53. [PMID: 34213069 DOI: 10.1002/kjm2.12401] [Reference Citation Analysis]
50 Omer DM, Dozier J, Cao Z, Zhu H, McCain DA. A case report on a large, peduncular intra-abdominal hepatocellular carcinoma extending into the retroperitoneum. Clin Case Rep 2021;9:1288-91. [PMID: 33768828 DOI: 10.1002/ccr3.3751] [Reference Citation Analysis]
51 Kudo M. Cabozantinib as a Second-Line Agent in Advanced Hepatocellular Carcinoma. Liver Cancer. 2018;7:123-133. [PMID: 29888203 DOI: 10.1159/000488542] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
52 Zhang N, Hu Z, Qiang Y, Zhu X. Circulating miR-130b- and miR-21-based diagnostic markers and therapeutic targets for hepatocellular carcinoma. Mol Genet Genomic Med. 2019;7:e1012. [PMID: 31660696 DOI: 10.1002/mgg3.1012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
53 Liu JY, Chiang T, Liu CH, Chern GG, Lin TT, Gao DY, Chen Y. Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer. Mol Ther 2015;23:1772-82. [PMID: 26278330 DOI: 10.1038/mt.2015.147] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
54 Shen K, Ji L, Lu B, Xu C, Gong C, Morahan G, Wang Z. Andrographolide inhibits tumor angiogenesis via blocking VEGFA/VEGFR2-MAPKs signaling cascade. Chemico-Biological Interactions 2014;218:99-106. [DOI: 10.1016/j.cbi.2014.04.020] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.3] [Reference Citation Analysis]
55 Xia H, Chen J, Shi M, Gao H, Sekar K, Seshachalam VP, Ooi LLP, Hui KM. EDIL3 is a novel regulator of epithelial-mesenchymal transition controlling early recurrence of hepatocellular carcinoma. Journal of Hepatology 2015;63:863-73. [DOI: 10.1016/j.jhep.2015.05.005] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 5.7] [Reference Citation Analysis]
56 Dika IE, Abou-Alfa GK. Treatment options after sorafenib failure in patients with hepatocellular carcinoma. Clin Mol Hepatol 2017;23:273-9. [PMID: 29151326 DOI: 10.3350/cmh.2017.0108] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
57 Gao S, Tang L, Cui Y, Li X, Zhang X, Shan J, Sun Y, Zhang X. Tumor angiogenesis-related parameters in multi-phase enhanced CT correlated with outcomes of hepatocellular carcinoma patients after radical hepatectomy. European Journal of Surgical Oncology (EJSO) 2016;42:538-44. [DOI: 10.1016/j.ejso.2016.01.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
58 Fahey S, Dempsey E, Long A. The role of chemokines in acute and chronic hepatitis C infection. Cell Mol Immunol 2014;11:25-40. [PMID: 23954947 DOI: 10.1038/cmi.2013.37] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 4.8] [Reference Citation Analysis]
59 Tampaki M, Doumba PP, Deutsch M, Koskinas J. Circulating biomarkers of hepatocellular carcinoma response after locoregional treatments: New insights. World J Hepatol 2015; 7(14): 1834-1842 [PMID: 26207165 DOI: 10.4254/wjh.v7.i14.1834] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
60 Coleman SJ, Grose RP, Kocher HM. Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma. J Hepatocell Carcinoma 2014;1:43-54. [PMID: 27508175 DOI: 10.2147/JHC.S48958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
61 Matsuda M, Seki E. Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis. Semin Liver Dis 2020;40:307-20. [PMID: 32242330 DOI: 10.1055/s-0040-1708876] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
62 Wen Y, Zhou X, Lu M, He M, Tian Y, Liu L, Wang M, Tan W, Deng Y, Yang X, Mayer MP, Zou F, Chen X. Bclaf1 promotes angiogenesis by regulating HIF-1α transcription in hepatocellular carcinoma. Oncogene 2019;38:1845-59. [PMID: 30367150 DOI: 10.1038/s41388-018-0552-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
63 Bahrami A, Shahidsales S, Khazaei M, Ghayour-mobarhan M, Maftouh M, Hassanian SM, Avan A. C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives: c-Met in gastrointestinal cancers. J Cell Physiol 2017;232:2657-73. [DOI: 10.1002/jcp.25794] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 6.4] [Reference Citation Analysis]
64 Massimi M, Ragusa F, Cardarelli S, Giorgi M. Targeting Cyclic AMP Signalling in Hepatocellular Carcinoma. Cells 2019;8:E1511. [PMID: 31775395 DOI: 10.3390/cells8121511] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
65 Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinog 2017;16:1. [PMID: 28694740 DOI: 10.4103/jcar.JCar_9_16] [Cited by in Crossref: 313] [Cited by in F6Publishing: 221] [Article Influence: 62.6] [Reference Citation Analysis]
66 Vanderborght B, Lefere S, Vlierberghe HV, Devisscher L. The Angiopoietin/Tie2 Pathway in Hepatocellular Carcinoma. Cells 2020;9:E2382. [PMID: 33143149 DOI: 10.3390/cells9112382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
67 Özkan A, Stolley D, Cressman ENK, McMillin M, DeMorrow S, Yankeelov TE, Rylander MN. The Influence of Chronic Liver Diseases on Hepatic Vasculature: A Liver-on-a-chip Review. Micromachines (Basel) 2020;11:E487. [PMID: 32397454 DOI: 10.3390/mi11050487] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
68 Han LL, Lv Y, Guo H, Ruan ZP, Nan KJ. Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy. World J Gastroenterol 2014; 20(30): 10249-10261 [PMID: 25132742 DOI: 10.3748/wjg.v20.i30.10249] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
69 Han L, Huang C, Zhang S. The RNA‐binding protein SORBS2 suppresses hepatocellular carcinoma tumourigenesis and metastasis by stabilizing RORA mRNA. Liver Int 2019;39:2190-203. [DOI: 10.1111/liv.14202] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
70 Park JO, Ryoo BY, Yen CJ, Kudo M, Yang L, Abada PB, Cheng R, Orlando M, Zhu AX, Okusaka T. Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis. Oncotarget. 2016;7:75482-75491. [PMID: 27776351 DOI: 10.18632/oncotarget.12780] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
71 Zhu AX. Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives. Semin Oncol. 2012;39:493-502. [PMID: 22846866 DOI: 10.1053/j.seminoncol.2012.05.014] [Cited by in Crossref: 62] [Cited by in F6Publishing: 52] [Article Influence: 6.2] [Reference Citation Analysis]
72 Jeng KS, Sheen IS, Lin SS, Leu CM, Chang CF. The Role of Endoglin in Hepatocellular Carcinoma. Int J Mol Sci 2021;22:3208. [PMID: 33809908 DOI: 10.3390/ijms22063208] [Reference Citation Analysis]
73 Wang H, Lu Y, Liu R, Wang L, Liu Q, Han S. A Non-Invasive Nomogram for Preoperative Prediction of Microvascular Invasion Risk in Hepatocellular Carcinoma. Front Oncol 2021;11:745085. [PMID: 35004273 DOI: 10.3389/fonc.2021.745085] [Reference Citation Analysis]
74 Choi SH, Park JY, Kang W, Kim SU, Kim do Y, Ahn SH, Ro SW, Han KH. Knockdown of HIF-1α and IL-8 induced apoptosis of hepatocellular carcinoma triggers apoptosis of vascular endothelial cells. Apoptosis 2016;21:85-95. [PMID: 26467924 DOI: 10.1007/s10495-015-1185-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
75 Chen J, Jin R, Zhao J, Liu J, Ying H, Yan H, Zhou S, Liang Y, Huang D, Liang X, Yu H, Lin H, Cai X. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Cancer Letters 2015;367:1-11. [DOI: 10.1016/j.canlet.2015.06.019] [Cited by in Crossref: 111] [Cited by in F6Publishing: 121] [Article Influence: 15.9] [Reference Citation Analysis]
76 Chen MC, Huang HH, Lai CY, Lin YJ, Liou JP, Lai MJ, Li YH, Teng CM, Yang CR. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma. Oncotarget 2016;7:402-17. [PMID: 26587975 DOI: 10.18632/oncotarget.6352] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
77 Shiragannavar VD, Gowda NGS, Kumar DP, Mirshahi F, Santhekadur PK. Withaferin A Acts as a Novel Regulator of Liver X Receptor-α in HCC. Front Oncol 2020;10:628506. [PMID: 33585254 DOI: 10.3389/fonc.2020.628506] [Reference Citation Analysis]
78 Matsuki M, Hoshi T, Yamamoto Y, Ikemori-Kawada M, Minoshima Y, Funahashi Y, Matsui J. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med. 2018;7:2641-2653. [PMID: 29733511 DOI: 10.1002/cam4.1517] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 10.5] [Reference Citation Analysis]
79 Su J, Huang Y, Wang Y, Li R, Deng W, Zhang H, Xiong H. CPNE1 is a potential prognostic biomarker, associated with immune infiltrates and promotes progression of hepatocellular carcinoma. Cancer Cell Int 2022;22:67. [PMID: 35139863 DOI: 10.1186/s12935-022-02485-2] [Reference Citation Analysis]
80 Zhao C, Zhao Z, Wang Z, Hu L, Wang H, Fang Z. Supervillin promotes tumor angiogenesis in liver cancer. Oncol Rep 2020;44:674-84. [PMID: 32468064 DOI: 10.3892/or.2020.7621] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
81 Chen Y, Gao DY, Huang L. In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv Drug Deliv Rev. 2015;81:128-141. [PMID: 24859533 DOI: 10.1016/j.addr.2014.05.009] [Cited by in Crossref: 352] [Cited by in F6Publishing: 334] [Article Influence: 44.0] [Reference Citation Analysis]
82 Hu F, Sun X, Li G, Wu Q, Chen Y, Yang X, Luo X, Hu J, Wang G. Inhibition of SIRT2 limits tumour angiogenesis via inactivation of the STAT3/VEGFA signalling pathway. Cell Death Dis 2018;10:9. [PMID: 30584257 DOI: 10.1038/s41419-018-1260-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
83 Palmer DH, Ma YT, Peck-Radosavljevic M, Ross P, Graham J, Fartoux L, Deptala A, Studeny M, Schnell D, Hocke J, Loembé AB, Meyer T. A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma. Br J Cancer 2018;118:1162-8. [PMID: 29563636 DOI: 10.1038/s41416-018-0051-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
84 Yen CJ, Kim TY, Feng YH, Chao Y, Lin DY, Ryoo BY, Huang DC, Schnell D, Hocke J, Loembé AB, Cheng AL. A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma. Liver Cancer 2018;7:165-78. [PMID: 29888206 DOI: 10.1159/000486460] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
85 Xie H, Xing C, Wei B, Xu X, Wu L, Wu J, Chen L, Cao G, Chen H, Meng X, Yin S, Zhou L, Zheng S. Polymorphisms of FGFR1 in HBV-related hepatocellular carcinoma. Tumour Biol 2015;36:8881-6. [PMID: 26069105 DOI: 10.1007/s13277-015-3643-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
86 Chang SX, Li GW, Chen Y, Bao H, Zhou L, Yuan J, Wu DM, Dai YM. Characterizing venous vasculatures of hepatocellular carcinoma using a multi-breath-hold two-dimensional susceptibility weighted imaging. PLoS One 2013;8:e65895. [PMID: 23799060 DOI: 10.1371/journal.pone.0065895] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
87 Kudo M. Cabozantinib for advanced hepatocellular carcinoma. Hepatobiliary Surg Nutr 2019;8:153-6. [PMID: 31098366 DOI: 10.21037/hbsn.2018.11.22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
88 Lee YH, Tai D, Yip C, Choo SP, Chew V. Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond. Front Immunol 2020;11:568759. [PMID: 33117354 DOI: 10.3389/fimmu.2020.568759] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
89 Bertino G, Demma S, Ardiri A, Proiti M, Mangia A, Gruttadauria S, Toro A, Di Carlo I, Malaguarnera G, Bertino N. The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies. Biomed Res Int. 2015;2015:731469. [PMID: 25893197 DOI: 10.1155/2015/731469] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
90 Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12:408-424. [PMID: 26054909 DOI: 10.1038/nrclinonc.2015.103] [Cited by in Crossref: 260] [Cited by in F6Publishing: 261] [Article Influence: 37.1] [Reference Citation Analysis]
91 Zhong M, Zhang X, Li B, Chen CS, Ji GL, Li SX, Bi DQ, Zhao QC, Shi H. Expression of MSP58 in hepatocellular carcinoma. Med Oncol 2013;30:539. [PMID: 23519485 DOI: 10.1007/s12032-013-0539-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
92 Xu L, Xu S, Wang H, Zhang J, Chen Z, Pan L, Wang J, Wei X, Xie H, Zhou L, Zheng S, Xu X. Enhancing the Efficacy and Safety of Doxorubicin against Hepatocellular Carcinoma through a Modular Assembly Approach: The Combination of Polymeric Prodrug Design, Nanoparticle Encapsulation, and Cancer Cell-Specific Drug Targeting. ACS Appl Mater Interfaces 2018;10:3229-40. [PMID: 29313660 DOI: 10.1021/acsami.7b14496] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 7.8] [Reference Citation Analysis]
93 Dewerchin M, Carmeliet P. Placental growth factor in cancer. Expert Opinion on Therapeutic Targets 2014;18:1339-54. [DOI: 10.1517/14728222.2014.948420] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 5.4] [Reference Citation Analysis]
94 Cheng CC, Chao WT, Liao CC, Shih JH, Lai YS, Hsu YH, Liu YH. The Roles Of Angiogenesis And Cancer Stem Cells In Sorafenib Drug Resistance In Hepatocellular Carcinoma. Onco Targets Ther 2019;12:8217-27. [PMID: 31632072 DOI: 10.2147/OTT.S217468] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
95 Zhang XF, Chao J, Pan QZ, Pan K, Weng DS, Wang QJ, Zhao JJ, He J, Liu Q, Jiang SS, Chen CL, Zhang HX, Xia JC. Overexpression of WWP1 promotes tumorigenesis and predicts unfavorable prognosis in patients with hepatocellular carcinoma. Oncotarget 2015;6:40920-33. [PMID: 26506518 DOI: 10.18632/oncotarget.5712] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
96 Yildiz I, Deniz S, Ozer A, Caliskan K. Trans-Arterial Chemoembolization with 50 μm Degradable Starch Microspheres Versus 300–500 μm Drug Eluting Beads in Hepatocellular Carcinoma: A Comparative Analysis of Initial Treatment Outcomes. Journal of the Belgian Society of Radiology 2022;106:10. [DOI: 10.5334/jbsr.2594] [Reference Citation Analysis]
97 Talaat RM, Adel S, Salem TA, Nasr MI. Correlation between angiogenic/inflammatory mediators in Wister rat model of liver dysplasia. Journal of Immunoassay and Immunochemistry 2016;37:472-84. [DOI: 10.1080/15321819.2016.1157490] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
98 Lin YM, Taiji R, Calandri M, Odisio BC. Tumor Biomarkers and Interventional Oncology: Impact on Local Outcomes for Liver and Lung Malignancy. Curr Oncol Rep 2021;23:67. [PMID: 33855606 DOI: 10.1007/s11912-021-01056-4] [Reference Citation Analysis]
99 Li T, Ge G, Zhang H, Wang R, Liu Y, Zhang Q, Yue Z, Ma W, Li W, Zhang J, Yang H, Wang P, Zhao J, Fang Y, Xie Q, Wang M, Li Y, Zhu H, Li H. HM-3-HSA exhibits potent anti-angiogenesis and antitumor activity in hepatocellular carcinoma. Eur J Pharm Sci 2021;167:106017. [PMID: 34555448 DOI: 10.1016/j.ejps.2021.106017] [Reference Citation Analysis]
100 Mahmoud AM, Zaki AR, Hassan ME, Mostafa-hedeab G. Commiphora molmol resin attenuates diethylnitrosamine/phenobarbital-induced hepatocarcinogenesis by modulating oxidative stress, inflammation, angiogenesis and Nrf2/ARE/HO-1 signaling. Chemico-Biological Interactions 2017;270:41-50. [DOI: 10.1016/j.cbi.2017.04.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
101 Tumanova UN, Shchegolev AI. Angiogenesis in hepatocellular carcinoma. Biol Bull Rev 2015;5:568-78. [DOI: 10.1134/s2079086415060080] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
102 Hu Y, Chen T, Chau G, Yang T, Liu C, Chen M, Chang PM, Chen T, Hsiao M, Huang CF, Chen S. Baseline hypertension: New insight into the potential predictors of survival in patients with hepatocellular carcinoma. International Journal of Cardiology 2013;168:2979-81. [DOI: 10.1016/j.ijcard.2013.04.106] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
103 Yen CC, Yen CJ. Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein. Expert Opin Drug Saf 2021;:1-10. [PMID: 34668832 DOI: 10.1080/14740338.2022.1995353] [Reference Citation Analysis]
104 Zhang X, Wu Z, Peng Y, Li D, Jiang Y, Pan F, Li Y, Lai Y, Cui Z, Zhang K. Correlationship between Ki67, VEGF, and p53 and Hepatocellular Carcinoma Recurrence in Liver Transplant Patients. Biomed Res Int 2021;2021:6651397. [PMID: 33954191 DOI: 10.1155/2021/6651397] [Reference Citation Analysis]
105 Luo Q, Yang G, Gao H, Wang Y, Luo C, Ma X, Gao Y, Li X, Zhao H, Jia B, Shi J, Wang F. An Integrin Alpha 6-Targeted Radiotracer with Improved Receptor Binding Affinity and Tumor Uptake. Bioconjug Chem 2020;31:1510-21. [PMID: 32347718 DOI: 10.1021/acs.bioconjchem.0c00170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Miller H, Czigany Z, Lurje I, Reichelt S, Bednarsch J, Strnad P, Trautwein C, Roderburg C, Tacke F, Gaisa NT, Knüchel-Clarke R, Neumann UP, Lurje G. Impact of Angiogenesis- and Hypoxia-Associated Polymorphisms on Tumor Recurrence in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection. Cancers (Basel) 2020;12:E3826. [PMID: 33352897 DOI: 10.3390/cancers12123826] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Wang S, Zhu Y, He H, Liu J, Xu L, Zhang H, Liu H, Liu W, Liu Y, Pan D, Chen L, Wu Q, Xu J, Gu J. Sorafenib suppresses growth and survival of hepatoma cells by accelerating degradation of enhancer of zeste homolog 2. Cancer Sci 2013;104:750-9. [PMID: 23421437 DOI: 10.1111/cas.12132] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
108 王玉霞, 刘贵秋, 刘辉, 张传山. BMP-2在肝细胞癌中表达及与肿瘤血管生成的关系. 世界华人消化杂志 2017; 25(13): 1150-1158 [DOI: 10.11569/wcjd.v25.i13.1150] [Reference Citation Analysis]
109 Reig M, Galle PR, Kudo M, Finn R, Llovet JM, Metti AL, Schelman WR, Liang K, Wang C, Widau RC, Abada P, Zhu AX. Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. Liver Int 2021;41:598-607. [PMID: 33188713 DOI: 10.1111/liv.14731] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
110 Wright T, Wang Y, Bedford MT. The Role of the PRMT5-SND1 Axis in Hepatocellular Carcinoma. Epigenomes 2021;5:2. [PMID: 33768972 DOI: 10.3390/epigenomes5010002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
111 Abd El Aziz MA, Facciorusso A, Nayfeh T, Saadi S, Elnaggar M, Cotsoglou C, Sacco R. Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma. Vaccines (Basel) 2020;8:E616. [PMID: 33086471 DOI: 10.3390/vaccines8040616] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
112 Younis NS, Ghanim AMH, Saber S. Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma. Sci Rep 2019;9:19095. [PMID: 31836811 DOI: 10.1038/s41598-019-55666-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
113 Goyal L, Zheng H, Yurgelun MB, Abrams TA, Allen JN, Cleary JM, Knowles M, Regan E, Reardon A, Khachatryan A, Jain RK, Nardi V, Borger DR, Duda DG, Zhu AX. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Cancer 2017;123:1979-88. [PMID: 28192597 DOI: 10.1002/cncr.30571] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 10.8] [Reference Citation Analysis]
114 Cao G, Li X, Qin C, Li J. Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis. Med Sci Monit. 2015;21:3144-3151. [PMID: 26476711 DOI: 10.12659/msm.894617] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
115 Zhu D, Li W, Wen HM, Yu S, Miao ZY, Kang A, Zhang A. Silver nanoparticles-enhanced time-resolved fluorescence sensor for VEGF(165) based on Mn-doped ZnS quantum dots. Biosens Bioelectron. 2015;74:1053-1060. [PMID: 26276542 DOI: 10.1016/j.bios.2015.08.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
116 Liang Y, Luo H, Zhang H, Dong Y, Bao Y. Oncogene Delta/Notch-Like EGF-Related Receptor Promotes Cell Proliferation, Invasion, and Migration in Hepatocellular Carcinoma and Predicts a Poor Prognosis. Cancer Biother Radiopharm 2018;33:380-6. [PMID: 30235011 DOI: 10.1089/cbr.2018.2460] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
117 Zhou C, Shi Q, Liu J, Huang S, Yang C, Xiong B. Effect of Inhibiting Tumor Angiogenesis After Embolization in the Treatment of HCC with Apatinib-Loaded p(N-Isopropyl-Acrylamide-co-Butyl Methyl Acrylate) Temperature-Sensitive Nanogel. J Hepatocell Carcinoma 2020;7:447-56. [PMID: 33409168 DOI: 10.2147/JHC.S282209] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
118 Huang CY, Wang H, Liao W, Han F, Li YQ, Chen SW, Lao XM. Transforming Growth Factor β is a Poor Prognostic Factor and Inhibits the Favorable Prognostic Value of CD8+ CTL in Human Hepatocellular Carcinoma. J Immunother 2017;40:175-86. [PMID: 28394813 DOI: 10.1097/CJI.0000000000000166] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
119 Zhou C, Yao Q, Zhang H, Guo X, Liu J, Shi Q, Huang S, Xiong B. Combining transcatheter arterial embolization with iodized oil containing Apatinib inhibits HCC growth and metastasis. Sci Rep 2020;10:2964. [PMID: 32076049 DOI: 10.1038/s41598-020-59746-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
120 Balzarini P, Benetti A, Invernici G, Cristini S, Zicari S, Caruso A, Gatta LB, Berenzi A, Imberti L, Zanotti C, Portolani N, Giulini SM, Ferrari M, Ciusani E, Navone SE, Canazza A, Parati EA, Alessandri G. Transforming growth factor-beta1 induces microvascular abnormalities through a down-modulation of neural cell adhesion molecule in human hepatocellular carcinoma. Lab Invest 2012;92:1297-309. [PMID: 22732936 DOI: 10.1038/labinvest.2012.94] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
121 Dong Y, Xie X, Wang Z, Hu C, Zheng Q, Wang Y, Chen R, Xue T, Chen J, Gao D. Increasing matrix stiffness upregulates vascular endothelial growth factor expression in hepatocellular carcinoma cells mediated by integrin β1. Biochem Biophys Res Commun. 2014;444:427-432. [PMID: 24472554 DOI: 10.1016/j.bbrc.2014.01.079] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 6.0] [Reference Citation Analysis]
122 Singhal A, Jayaraman M, Dhanasekaran DN, Kohli V. Molecular and serum markers in hepatocellular carcinoma: Predictive tools for prognosis and recurrence. Critical Reviews in Oncology/Hematology 2012;82:116-40. [DOI: 10.1016/j.critrevonc.2011.05.005] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
123 Fu C, An N, Liu J, A J, Zhang B, Liu M, Zhang Z, Fu L, Tian X, Wang D, Dong JT. The transcription factor ZFHX3 is crucial for the angiogenic function of hypoxia-inducible factor 1α in liver cancer cells. J Biol Chem 2020;295:7060-74. [PMID: 32277050 DOI: 10.1074/jbc.RA119.012131] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
124 Liu M, Jiang L, Guan XY. The genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update. Protein Cell. 2014;5:673-691. [PMID: 24916440 DOI: 10.1007/s13238- 014-0065-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
125 Yang H, Wang J, Fan J, Zhang Y, Zhao J, Dai X, Liu Q, Shen Y, Liu C, Sun W, Sun Y. Ilexgenin A exerts anti-inflammation and anti-angiogenesis effects through inhibition of STAT3 and PI3K pathways and exhibits synergistic effects with Sorafenib on hepatoma growth. Toxicology and Applied Pharmacology 2017;315:90-101. [DOI: 10.1016/j.taap.2016.12.008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
126 Iwakiri Y, Shah V, Rockey DC. Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions. J Hepatol. 2014;61:912-924. [PMID: 24911462 DOI: 10.1016/j.jhep.2014.05.047] [Cited by in Crossref: 162] [Cited by in F6Publishing: 141] [Article Influence: 20.3] [Reference Citation Analysis]
127 Wu DD, Wang DY, Li HM, Guo JC, Duan SF, Ji XY. Hydrogen Sulfide as a Novel Regulatory Factor in Liver Health and Disease. Oxid Med Cell Longev 2019;2019:3831713. [PMID: 30805080 DOI: 10.1155/2019/3831713] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
128 Zhu P, Lv J, Yang Z, Guo L, Zhang L, Li M, Han W, Chen X, Zhuang H, Lu F. Protocadherin 9 inhibits epithelial-mesenchymal transition and cell migration through activating GSK-3β in hepatocellular carcinoma. Biochem Biophys Res Commun 2014;452:567-74. [PMID: 25172662 DOI: 10.1016/j.bbrc.2014.08.101] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
129 Lin Y, Yang X, Liu W, Li B, Yin W, Shi Y, He R. Chemerin has a protective role in hepatocellular carcinoma by inhibiting the expression of IL-6 and GM-CSF and MDSC accumulation. Oncogene 2017;36:3599-608. [DOI: 10.1038/onc.2016.516] [Cited by in Crossref: 60] [Cited by in F6Publishing: 63] [Article Influence: 12.0] [Reference Citation Analysis]
130 Fang JH, Zhou HC, Zhang C, Shang LR, Zhang L, Xu J, Zheng L, Yuan Y, Guo RP, Jia WH, Yun JP, Chen MS, Zhang Y, Zhuang SM. A novel vascular pattern promotes metastasis of hepatocellular carcinoma in an epithelial-mesenchymal transition-independent manner. Hepatology. 2015;62:452-465. [PMID: 25711742 DOI: 10.1002/hep.27760] [Cited by in Crossref: 74] [Cited by in F6Publishing: 74] [Article Influence: 10.6] [Reference Citation Analysis]
131 Nishikawa H, Osaki Y, Iguchi E, Takeda H, Nakajima J, Matsuda F, Sakamoto A, Henmi S, Hatamaru K, Saito S, Nasu A, Kita R, Kimura T. Comparison of the efficacy of transcatheter arterial chemoembolization and sorafenib for advanced hepatocellular carcinoma. Exp Ther Med 2012;4:381-6. [PMID: 23181103 DOI: 10.3892/etm.2012.611] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
132 Yu LX, Ling Y, Wang HY. Role of nonresolving inflammation in hepatocellular carcinoma development and progression. NPJ Precis Oncol 2018;2:6. [PMID: 29872724 DOI: 10.1038/s41698-018-0048-z] [Cited by in Crossref: 75] [Cited by in F6Publishing: 82] [Article Influence: 18.8] [Reference Citation Analysis]
133 Shi Y, Xu T, Li L, Chen X. Over-expression of VEGF and MMP-9 in residual tumor cells of hepatocellular carcinoma after embolization with lipidol. J Huazhong Univ Sci Technol [Med Sci ] 2013;33:90-5. [DOI: 10.1007/s11596-013-1077-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
134 Liu P, Atkinson SJ, Akbareian SE, Zhou Z, Munsterberg A, Robinson SD, Bao Y. Sulforaphane exerts anti-angiogenesis effects against hepatocellular carcinoma through inhibition of STAT3/HIF-1α/VEGF signalling. Sci Rep 2017;7:12651. [PMID: 28978924 DOI: 10.1038/s41598-017-12855-w] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
135 Fan Z, Zheng W, Li H, Wu W, Liu X, Sun Z, Hu H, Du L, Jia Q, Liu Q. LOXL2 upregulates hypoxia‑inducible factor‑1α signaling through Snail‑FBP1 axis in hepatocellular carcinoma cells. Oncol Rep 2020;43:1641-9. [PMID: 32323822 DOI: 10.3892/or.2020.7541] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
136 Vogel A, Bathon M, Saborowski A. Advances in systemic therapy for the first-line treatment of unresectable HCC. Expert Rev Anticancer Ther 2021;21:621-8. [PMID: 33499684 DOI: 10.1080/14737140.2021.1882855] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
137 Huang XY, Yao JG, Huang HD, Wang C, Ma Y, Xia Q, Long XD. MicroRNA-429 Modulates Hepatocellular Carcinoma Prognosis and Tumorigenesis. Gastroenterol Res Pract 2013;2013:804128. [PMID: 24204382 DOI: 10.1155/2013/804128] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
138 Zhu LM, Shi DM, Dai Q, Cheng XJ, Yao WY, Sun PH, Ding Y, Qiao MM, Wu YL, Jiang SH, Tu SP. Tumor suppressor XAF1 induces apoptosis, inhibits angiogenesis and inhibits tumor growth in hepatocellular carcinoma. Oncotarget 2014;5:5403-15. [PMID: 24980821 DOI: 10.18632/oncotarget.2114] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
139 Berretta M, Rinaldi L, Di Benedetto F, Lleshi A, De Re V, Facchini G, De Paoli P, Di Francia R. Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma. Front Pharmacol 2016;7:428. [PMID: 27881963 DOI: 10.3389/fphar.2016.00428] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
140 Xue X, Gao W, Sun B, Xu Y, Han B, Wang F, Zhang Y, Sun J, Wei J, Lu Z, Zhu Y, Sato Y, Sekido Y, Miao Y, Kondo Y. Vasohibin 2 is transcriptionally activated and promotes angiogenesis in hepatocellular carcinoma. Oncogene 2013;32:1724-34. [PMID: 22614011 DOI: 10.1038/onc.2012.177] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 5.2] [Reference Citation Analysis]
141 Cabiati M, Gaggini M, De Simone P, Del Ry S. Evaluation of Apelin/APJ system expression in hepatocellular carcinoma as a function of clinical severity. Clin Exp Med 2021;21:269-75. [DOI: 10.1007/s10238-020-00672-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
142 Chen CL, Wang Y, Pan QZ, Tang Y, Wang QJ, Pan K, Huang LX, He J, Zhao JJ, Jiang SS, Zhang XF, Zhang HX, Zhou ZQ, Weng de S, Xia JC. Bromodomain-containing protein 7 (BRD7) as a potential tumor suppressor in hepatocellular carcinoma. Oncotarget 2016;7:16248-61. [PMID: 26919247 DOI: 10.18632/oncotarget.7637] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
143 Tao Y, Hu K, Tan F, Zhang S, Zhou M, Luo J, Wang Z. SH3-domain binding protein 1 in the tumor microenvironment promotes hepatocellular carcinoma metastasis through WAVE2 pathway. Oncotarget 2016;7:18356-70. [PMID: 26933917 DOI: 10.18632/oncotarget.7786] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
144 Chen SS, Yu KK, Ling QX, Huang C, Li N, Zheng JM, Bao SX, Cheng Q, Zhu MQ, Chen MQ. The combination of three molecular markers can be a valuable predictive tool for the prognosis of hepatocellular carcinoma patients. Sci Rep. 2016;6:24582. [PMID: 27079415 DOI: 10.1038/srep24582] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
145 Liu HT, Jiang MJ, Deng ZJ, Li L, Huang JL, Liu ZX, Li LQ, Zhong JH. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges. Front Oncol 2021;11:737497. [PMID: 34745958 DOI: 10.3389/fonc.2021.737497] [Reference Citation Analysis]
146 Hu C, Li W, Tian F, Jiang K, Liu X, Cen J, He Q, Qiu Z, Kienast Y, Wang Z, Zhang H, Ji Y, Hu J, Hui L. Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma. J Hepatol 2018;68:465-75. [PMID: 29113912 DOI: 10.1016/j.jhep.2017.10.028] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
147 Herzog J, Ehrlich SM, Pfitzer L, Liebl J, Fröhlich T, Arnold GJ, Mikulits W, Haider C, Vollmar AM, Zahler S. Cyclin-dependent kinase 5 stabilizes hypoxia-inducible factor-1α: a novel approach for inhibiting angiogenesis in hepatocellular carcinoma. Oncotarget 2016;7:27108-21. [PMID: 27027353 DOI: 10.18632/oncotarget.8342] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
148 Kaps L, Schuppan D. Targeting Cancer Associated Fibroblasts in Liver Fibrosis and Liver Cancer Using Nanocarriers. Cells 2020;9:E2027. [PMID: 32899119 DOI: 10.3390/cells9092027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
149 Chen Y, Huang Y, Reiberger T, Duyverman AM, Huang P, Samuel R, Hiddingh L, Roberge S, Koppel C, Lauwers GY, Zhu AX, Jain RK, Duda DG. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology. 2014;59:1435-1447. [PMID: 24242874 DOI: 10.1002/hep.26790] [Cited by in Crossref: 114] [Cited by in F6Publishing: 116] [Article Influence: 14.3] [Reference Citation Analysis]
150 Kurhe Y, Caputo M, Cansby E, Xia Y, Kumari S, Anand SK, Howell BW, Marschall HU, Mahlapuu M. Antagonizing STK25 Signaling Suppresses the Development of Hepatocellular Carcinoma Through Targeting Metabolic, Inflammatory, and Pro-Oncogenic Pathways. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00208-3. [PMID: 34624527 DOI: 10.1016/j.jcmgh.2021.09.018] [Reference Citation Analysis]
151 Harding JJ, Abou-Alfa GK. Treating advanced hepatocellular carcinoma: How to get out of first gear. Cancer. 2014;120:3122-3130. [PMID: 24898783 DOI: 10.1002/cncr.28850] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
152 Guo JC, Liu Z, Yang YJ, Guo M, Zhang JQ, Zheng JF. KDM5B promotes self-renewal of hepatocellular carcinoma cells through the microRNA-448-mediated YTHDF3/ITGA6 axis. J Cell Mol Med 2021. [PMID: 33829656 DOI: 10.1111/jcmm.16342] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
153 Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, Ochiai H, Kitahara S, Unan EC, Reddy TP, Fan C, Huang P, Bardeesy N, Zhu AX, Jain RK, Duda DG. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology. 2015;61:1591-1602. [PMID: 25529917 DOI: 10.1002/hep.27665] [Cited by in Crossref: 228] [Cited by in F6Publishing: 233] [Article Influence: 32.6] [Reference Citation Analysis]
154 Cerrito L, Santopaolo F, Monti F, Pompili M, Gasbarrini A, Ponziani FR. Advances in pharmacotherapeutics for hepatocellular carcinoma. Expert Opin Pharmacother 2021;22:1343-54. [PMID: 33637024 DOI: 10.1080/14656566.2021.1892074] [Reference Citation Analysis]
155 Soule E, Matteo J. Finally, a Minimally Invasive Option for Intrahepatic Inferior Vena Cava Invasion by Hepatocellular Carcinoma. Gastrointest Tumors 2018;5:54-61. [PMID: 30574482 DOI: 10.1159/000491694] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
156 Ding F, Sun K, Sun N, Jiang Q, Cao M, Wu Z. iTRAQ-based proteomics reveals SOD2 as a potential salivary biomarker in liver cancer. Int J Biol Markers 2019;34:221-31. [PMID: 31041878 DOI: 10.1177/1724600819841619] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
157 Cheng CC, Chao WT, Shih JH, Lai YS, Hsu YH, Liu YH. Sorafenib combined with dasatinib therapy inhibits cell viability, migration, and angiogenesis synergistically in hepatocellular carcinoma. Cancer Chemother Pharmacol 2021;88:143-53. [PMID: 33860837 DOI: 10.1007/s00280-021-04272-8] [Reference Citation Analysis]
158 Wang X, Xiu P, Wang F, Zhong J, Wei H, Xu Z, Liu F, Li J. P18 peptide, a functional fragment of pigment epithelial-derived factor, inhibits angiogenesis in hepatocellular carcinoma via modulating VEGF/VEGFR2 signalling pathway. Oncol Rep 2017;38:755-66. [PMID: 28627623 DOI: 10.3892/or.2017.5719] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
159 Angart P, Vocelle D, Chan C, Walton SP. Design of siRNA Therapeutics from the Molecular Scale. Pharmaceuticals (Basel) 2013;6:440-68. [PMID: 23976875 DOI: 10.3390/ph6040440] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
160 Vrancken K, Paeshuyse J, Liekens S. Angiogenic activity of hepatitis B and C viruses. Antivir Chem Chemother. 2012;22:159-170. [PMID: 22182803 DOI: 10.3851/imp1987] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
161 Campagnolo L, Telesca C, Massimiani M, Stuhlmann H, Angelico M, Lenci I, Manzia TM, Tariciotti L, Lehmann G, Baiocchi L. Different expression of VEGF and EGFL7 in human hepatocellular carcinoma. Dig Liver Dis 2016;48:76-80. [PMID: 26542361 DOI: 10.1016/j.dld.2015.09.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
162 Liang Q, Kong L, Du Y, Zhu X, Tian J. Antitumorigenic and antiangiogenic efficacy of apatinib in liver cancer evaluated by multimodality molecular imaging. Exp Mol Med. 2019;51:76. [PMID: 31285418 DOI: 10.1038/s12276-019-0274-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
163 Kim S, Lee M, Song Y, Lee SY, Choi I, Park IS, Kim J, Kim JS, Kim KM, Seo HR. Argininosuccinate synthase 1 suppresses tumor progression through activation of PERK/eIF2α/ATF4/CHOP axis in hepatocellular carcinoma. J Exp Clin Cancer Res 2021;40:127. [PMID: 33838671 DOI: 10.1186/s13046-021-01912-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
164 Cho H, Yeh EC, Sinha R, Laurence TA, Bearinger JP, Lee LP. Single-step nanoplasmonic VEGF165 aptasensor for early cancer diagnosis. ACS Nano 2012;6:7607-14. [PMID: 22880609 DOI: 10.1021/nn203833d] [Cited by in Crossref: 95] [Cited by in F6Publishing: 83] [Article Influence: 9.5] [Reference Citation Analysis]
165 Mei Z, Jiao H, Wang W, Li J, Chen G, Xu Y. Polycomb chromobox 4 enhances migration and pulmonary metastasis of hepatocellular carcinoma cell line MHCC97L. Sci China Life Sci 2014;57:610-7. [PMID: 24838576 DOI: 10.1007/s11427-014-4663-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
166 Lee SH, Hayano K, Zhu AX, Sahani DV, Yoshida H. Water-Exchange-Modified Kinetic Parameters from Dynamic Contrast-Enhanced MRI as Prognostic Biomarkers of Survival in Advanced Hepatocellular Carcinoma Treated with Antiangiogenic Monotherapy. PLoS One. 2015;10:e0136725. [PMID: 26366997 DOI: 10.1371/journal.pone.0136725] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
167 Geng N, Jin Y, Li Y, Zhu S, Bai H. AKR1B10 Inhibitor Epalrestat Facilitates Sorafenib-Induced Apoptosis and Autophagy Via Targeting the mTOR Pathway in Hepatocellular Carcinoma. Int J Med Sci 2020;17:1246-56. [PMID: 32547320 DOI: 10.7150/ijms.42956] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
168 Thilakarathna WPDW, Rupasinghe HPV, Ridgway ND. Mechanisms by Which Probiotic Bacteria Attenuate the Risk of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:2606. [PMID: 33807605 DOI: 10.3390/ijms22052606] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
169 Kudo M, Okusaka T, Motomura K, Ohno I, Morimoto M, Seo S, Wada Y, Sato S, Yamashita T, Furukawa M, Aramaki T, Nadano S, Ohkawa K, Fujii H, Kudo T, Furuse J, Takai H, Homma G, Yoshikawa R, Zhu AX. Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial. J Gastroenterol 2020;55:627-39. [PMID: 32107609 DOI: 10.1007/s00535-020-01668-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
170 Prete A, Lo AS, Sadow PM, Bhasin SS, Antonello ZA, Vodopivec DM, Ullas S, Sims JN, Clohessy J, Dvorak AM, Sciuto T, Bhasin M, Murphy-Ullrich JE, Lawler J, Karumanchi SA, Nucera C. Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis. Clin Cancer Res 2018;24:6078-97. [PMID: 30076136 DOI: 10.1158/1078-0432.CCR-18-0693] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
171 Huang M, Chen C, Geng J, Han D, Wang T, Xie T, Wang L, Wang Y, Wang C, Lei Z, Chu X. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma. Cancer Lett 2017;398:12-21. [PMID: 28377178 DOI: 10.1016/j.canlet.2017.03.038] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 9.4] [Reference Citation Analysis]
172 Chen CK, Yu WH, Cheng TY, Chen MW, Su CY, Yang YC, Kuo TC, Lin MT, Huang YC, Hsiao M, Hua KT, Hung MC, Kuo ML. Inhibition of VEGF165/VEGFR2-dependent signaling by LECT2 suppresses hepatocellular carcinoma angiogenesis. Sci Rep 2016;6:31398. [PMID: 27507763 DOI: 10.1038/srep31398] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
173 Qin S, Gong X. Progression of systemic chemotherapy with oxaliplatin-containing regimens for advanced hepatocellular carcinoma in China. Hepat Oncol 2016;3:71-81. [PMID: 30191027 DOI: 10.2217/hep.15.42] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
174 Benechet AP, Iannacone M. Determinants of hepatic effector CD8+ T cell dynamics. J Hepatol 2017;66:228-33. [PMID: 27423427 DOI: 10.1016/j.jhep.2016.07.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
175 Zheng X, Gao S, Hua HQ, Yang AZ, Qin SK. Effect of ginsenoside Rg3 combined with sorafenib in inhibiting tumor growth and neovascularization in nude mice with in situ transplanted human hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2016; 24(5): 670-677 [DOI: 10.11569/wcjd.v24.i5.670] [Reference Citation Analysis]
176 Wang D, Han S, Wang X, Peng R, Li X. SOX5 promotes epithelial–mesenchymal transition and cell invasion via regulation of Twist1 in hepatocellular carcinoma. Med Oncol 2015;32. [DOI: 10.1007/s12032-014-0461-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 25] [Article Influence: 1.0] [Reference Citation Analysis]
177 Wang Q, Tian X, Zhang C, Wang Q. Upregulation of vasohibin-1 expression with angiogenesis and poor prognosis of hepatocellular carcinoma after curative surgery. Med Oncol 2012;29:2727-36. [DOI: 10.1007/s12032-011-0106-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
178 Suzuki E, Ooka Y, Chiba T, Kobayashi K, Kanogawa N, Motoyama T, Saito T, Ogasawara S, Tawada A, Yokosuka O. Incidental tumor necrosis caused by the interventional alteration of hepatic arterial flow in patients with advanced hepatocellular carcinoma. Clin J Gastroenterol 2015;8:41-6. [PMID: 25481841 DOI: 10.1007/s12328-014-0542-y] [Reference Citation Analysis]
179 Kong FH, Ye QF, Miao XY, Liu X, Huang SQ, Xiong L, Wen Y, Zhang ZJ. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma. Theranostics 2021;11:5464-90. [PMID: 33859758 DOI: 10.7150/thno.54822] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
180 Karmacharya MB, Sultan LR, Sehgal CM. Photoacoustic monitoring of oxygenation changes induced by therapeutic ultrasound in murine hepatocellular carcinoma. Sci Rep 2021;11:4100. [PMID: 33603035 DOI: 10.1038/s41598-021-83439-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
181 Lee SM, Kim-Ha J, Choi WY, Lee J, Kim D, Lee J, Choi E, Kim YJ. Interplay of genetic and epigenetic alterations in hepatocellular carcinoma. Epigenomics 2016;8:993-1005. [PMID: 27411963 DOI: 10.2217/epi-2016-0027] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
182 Pardee AD, Butterfield LH. Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. Oncoim-munology. 2012;1:48-55. [PMID: 22720211 DOI: 10.4161/onc-i.1.1.18344] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
183 Thompson AI, Conroy KP, Henderson NC. Hepatic stellate cells: central modulators of hepatic carcinogenesis. BMC Gastroenterol. 2015;15:63. [PMID: 26013123 DOI: 10.1186/s12876-015-0291-5] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 8.3] [Reference Citation Analysis]
184 Lee SH, Hayano K, Zhu AX, Sahani DV, Yoshida H. Advanced Hepatocellular Carcinoma: Perfusion Computed Tomography-Based Kinetic Parameter as a Prognostic Biomarker for Prediction of Patient Survival. J Comput Assist Tomogr 2015;39:687-96. [PMID: 26222909 DOI: 10.1097/RCT.0000000000000288] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
185 He C, You K, M.a B. New Pyroptosis -Associated Gene Signature for Overall Survival Forecast among Patients Suffering from Hepatocellular Carcinoma. Journal of Healthcare Engineering 2022;2022:1-12. [DOI: 10.1155/2022/6365485] [Reference Citation Analysis]
186 Chen JQ, Ou YL, Huang ZP, Hong YG, Tao YP, Wang ZG, Ni JS, Hao LQ, Lin H. MicroRNA-212-3p inhibits the Proliferation and Invasion of Human Hepatocellular Carcinoma Cells by Suppressing CTGF expression. Sci Rep 2019;9:9820. [PMID: 31285444 DOI: 10.1038/s41598-019-46088-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
187 Liu G, Yang ZF, Zhou PY, Zhou C, Guan RY, Sun BY, Fan J, Zhou J, Yi Y, Qiu SJ. ROR-α-1 inhibits the proliferation, invasion, and migration of hepatocellular carcinoma MHCC97H via downregulation of chemokine CXCL5. Cytokine 2020;129:155004. [PMID: 32058275 DOI: 10.1016/j.cyto.2020.155004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
188 Zhang H, Liu R, Sun L, Hu X. A Reliable Prognostic Model for HCC Using Histological Grades and the Expression Levels of Related Genes. J Oncol 2021;2021:9512774. [PMID: 34659413 DOI: 10.1155/2021/9512774] [Reference Citation Analysis]
189 Abraham JA, Yeghiazaryan K, Golubnitschaja O. Selective internal radiation therapy in treatment of hepatocellular carcinoma: new concepts of personalization. Per Med 2016;13:347-60. [PMID: 29749819 DOI: 10.2217/pme-2016-0014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
190 Affo S, Yu LX, Schwabe RF. The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer. Annu Rev Pathol 2017;12:153-86. [PMID: 27959632 DOI: 10.1146/annurev-pathol-052016-100322] [Cited by in Crossref: 183] [Cited by in F6Publishing: 189] [Article Influence: 30.5] [Reference Citation Analysis]
191 Hayano K, Yoshida H, Zhu AX, Sahani DV. Fractal analysis of contrast-enhanced CT images to predict survival of patients with hepatocellular carcinoma treated with sunitinib. Dig Dis Sci. 2014;59:1996-2003. [PMID: 24563237 DOI: 10.1007/s10620-014-3064-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
192 Sun H, Zhu MS, Wu WR, Shi XD, Xu LB. Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out. World J Hepatol 2014; 6(12): 830-835 [PMID: 25544869 DOI: 10.4254/wjh.v6.i12.830] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
193 Cho S, Min NG, Park W, Kim S, Kim D. Janus Microcarriers for Magnetic Field‐Controlled Combination Chemotherapy of Hepatocellular Carcinoma. Adv Funct Mater 2019;29:1901384. [DOI: 10.1002/adfm.201901384] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
194 Andrade FO, Furtado KS, Heidor R, Sandri S, Hebeda CB, Miranda MLP, Fernandes LHG, Yamamoto RC, Horst MA, Farsky SHP, Moreno FS. Antiangiogenic effects of the chemopreventive agent tributyrin, a butyric acid prodrug, during the promotion phase of hepatocarcinogenesis. Carcinogenesis 2019;40:979-88. [PMID: 30590392 DOI: 10.1093/carcin/bgy190] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
195 Li W, Shen S, Wu S, Chen Z, Hu C, Yan R. Regulation of tumorigenesis and metastasis of hepatocellular carcinoma tumor endothelial cells by microRNA-3178 and underlying mechanism. Biochemical and Biophysical Research Communications 2015;464:881-7. [DOI: 10.1016/j.bbrc.2015.07.057] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
196 Sun Y, Ma W, Yang Y, He M, Li A, Bai L, Yu B, Yu Z. Cancer nanotechnology: Enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapy. Asian J Pharm Sci 2019;14:581-94. [PMID: 32104485 DOI: 10.1016/j.ajps.2019.04.005] [Cited by in Crossref: 65] [Cited by in F6Publishing: 49] [Article Influence: 21.7] [Reference Citation Analysis]
197 Shneor D, Folberg R, Pe'er J, Honigman A, Frenkel S. Stable knockdown of CREB, HIF-1 and HIF-2 by replication-competent retroviruses abrogates the responses to hypoxia in hepatocellular carcinoma. Cancer Gene Ther 2017;24:64-74. [PMID: 27934882 DOI: 10.1038/cgt.2016.68] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
198 Tsang CM, Cheung KC, Cheung YC, Man K, Lui VW, Tsao SW, Feng Y. Berberine suppresses Id-1 expression and inhibits the growth and development of lung metastases in hepatocellular carcinoma. Biochim Biophys Acta. 2015;1852:541-551. [PMID: 25496992 DOI: 10.1016/j.bbadis.2014.12.004] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 6.5] [Reference Citation Analysis]
199 Weidle UH, Schmid D, Birzele F, Brinkmann U. MicroRNAs Involved in Metastasis of Hepatocellular Carcinoma: Target Candidates, Functionality and Efficacy in Animal Models and Prognostic Relevance. Cancer Genomics Proteomics 2020;17:1-21. [PMID: 31882547 DOI: 10.21873/cgp.20163] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
200 Rahman M, Almalki WH, Alrobaian M, Iqbal J, Alghamdi S, Alharbi KS, Alruwaili NK, Hafeez A, Shaharyar A, Singh T, Waris M, Kumar V, Beg S. Nanocarriers-loaded with natural actives as newer therapeutic interventions for treatment of hepatocellular carcinoma. Expert Opin Drug Deliv 2021;18:489-513. [PMID: 33225771 DOI: 10.1080/17425247.2021.1854223] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
201 Wu D, Li M, Gao Y, Tian W, Li J, Zhang Q, Liu Z, Zheng M, Wang H, Wang J, Teng T, Zhang L, Ji X, Xie Z, Ji A, Li Y. Peptide V3 Inhibits the Growth of Human Hepatocellular Carcinoma by Inhibiting the Ras/Raf/MEK/ERK Signaling Pathway. J Cancer 2019;10:1693-706. [PMID: 31205525 DOI: 10.7150/jca.29211] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
202 Chiang CL, Chan SK, Lee SF, Choi HC. First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Cancers (Basel) 2021;13:931. [PMID: 33668100 DOI: 10.3390/cancers13050931] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
203 Zhang H, Liu R, Sun L, Hu X. An lncRNA Model for Predicting the Prognosis of Hepatocellular Carcinoma Patients and ceRNA Mechanism. Front Mol Biosci 2021;8:749313. [PMID: 34869585 DOI: 10.3389/fmolb.2021.749313] [Reference Citation Analysis]
204 Tao Y, Wang J, Xu X. Emerging and Innovative Theranostic Approaches for Mesoporous Silica Nanoparticles in Hepatocellular Carcinoma: Current Status and Advances. Front Bioeng Biotechnol 2020;8:184. [PMID: 32211399 DOI: 10.3389/fbioe.2020.00184] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
205 Chen JL, Wang L, Li R, Jiao YF, Yu WF. High expression of endothelial progenitor cell-induced angiogenic markers is associated with bile acid levels in HCC. Oncol Lett 2020;20:2729-38. [PMID: 32782589 DOI: 10.3892/ol.2020.11815] [Reference Citation Analysis]
206 Sacco R, Faggioni L, Bargellini I, Romano A, Bertini M, Ginanni B, Battaglia V, Bertoni M, Bozzi E, Federici G, Metrangolo S, Parisi G, Neri E, Sodini E, Tumino E, Bresci G, Bartolozzi C. Treatment Response After Unusual Low Dose Sorafenib: Diagnosis with Perfusion CT and Follow-up in a Patient with Recurrent Hepatocellular Carcinoma. J Gastrointest Canc 2012;43:234-8. [DOI: 10.1007/s12029-012-9403-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
207 Hayano K, Lee SH, Yoshida H, Zhu AX, Sahani DV. Fractal analysis of CT perfusion images for evaluation of antiangiogenic treatment and survival in hepatocellular carcinoma. Acad Radiol. 2014;21:654-660. [PMID: 24703479 DOI: 10.1016/j.acra.2014.01.020] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
208 Kang YK, Yau T, Park JW, Lim HY, Lee TY, Obi S, Chan SL, Qin S, Kim RD, Casey M. Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Ann Oncol. 2015;26:2457-2463. [PMID: 26386123 DOI: 10.1093/annonc/mdv388] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 6.9] [Reference Citation Analysis]
209 Zhang H, Liu R, Sun L, Guo W, Ji X, Hu X. Comprehensive Analysis of Gene Expression Changes and Validation in Hepatocellular Carcinoma. Onco Targets Ther 2021;14:1021-31. [PMID: 33623390 DOI: 10.2147/OTT.S294500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
210 Scheller T, Hellerbrand C, Moser C, Schmidt K, Kroemer A, Brunner SM, Schlitt HJ, Geissler EK, Lang SA. mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma. Br J Cancer. 2015;112:841-850. [PMID: 25688743 DOI: 10.1038/bjc.2014.638] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
211 Sbenati RM, Zaraei SO, El-Gamal MI, Anbar HS, Tarazi H, Zoghbor MM, Mohamood NA, Khakpour MM, Zaher DM, Omar HA, Alach NN, Shehata MK, El-Gamal R. Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells. Eur J Med Chem 2021;210:113081. [PMID: 33310290 DOI: 10.1016/j.ejmech.2020.113081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
212 Jajamovich GH, Huang W, Besa C, Li X, Afzal A, Dyvorne HA, Taouli B. DCE-MRI of hepatocellular carcinoma: perfusion quantification with Tofts model versus shutter-speed model--initial experience. MAGMA 2016;29:49-58. [PMID: 26646522 DOI: 10.1007/s10334-015-0513-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
213 Ng KT, Xu A, Cheng Q, Guo DY, Lim ZX, Sun CK, Fung JH, Poon RT, Fan ST, Lo CM, Man K. Clinical relevance and therapeutic potential of angiopoietin-like protein 4 in hepatocellular carcinoma. Mol Cancer 2014;13:196. [PMID: 25148701 DOI: 10.1186/1476-4598-13-196] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
214 Indraccolo S. Insights into the regulation of tumor dormancy by angiogenesis in experimental tumors. Adv Exp Med Biol 2013;734:37-52. [PMID: 23143974 DOI: 10.1007/978-1-4614-1445-2_3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
215 Galle PR, Foerster F, Kudo M, Chan SL, Llovet JM, Qin S, Schelman WR, Chintharlapalli S, Abada PB, Sherman M, Zhu AX. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019;39:2214-2229. [PMID: 31436873 DOI: 10.1111/liv.14223] [Cited by in Crossref: 60] [Cited by in F6Publishing: 68] [Article Influence: 20.0] [Reference Citation Analysis]
216 Sahani DV, Jiang T, Hayano K, Duda DG, Catalano OA, Ancukiewicz M, Jain RK, Zhu AX. Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy. J Hematol Oncol. 2013;6:51. [PMID: 23842041 DOI: 10.1186/1756-8722-6-51] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
217 Espíndola KMM, Ferreira RG, Narvaez LEM, Silva Rosario ACR, da Silva AHM, Silva AGB, Vieira APO, Monteiro MC. Chemical and Pharmacological Aspects of Caffeic Acid and Its Activity in Hepatocarcinoma. Front Oncol 2019;9:541. [PMID: 31293975 DOI: 10.3389/fonc.2019.00541] [Cited by in Crossref: 71] [Cited by in F6Publishing: 61] [Article Influence: 23.7] [Reference Citation Analysis]
218 Tumanova UN, Shchegolev AI. Vascularization of hepatocellular carcinoma. Arkh patol 2015;77:50. [DOI: 10.17116/patol201577250-55] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
219 Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology. 2013;144:512-527. [PMID: 23313965 DOI: 10.1053/j.gastro.2013.01.002] [Cited by in Crossref: 395] [Cited by in F6Publishing: 387] [Article Influence: 43.9] [Reference Citation Analysis]
220 Villani R, Facciorusso A, Bellanti F, Tamborra R, Piscazzi A, Landriscina M, Vendemiale G, Serviddio G. DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment. PLoS One 2016;11:e0167934. [PMID: 27997563 DOI: 10.1371/journal.pone.0167934] [Cited by in Crossref: 56] [Cited by in F6Publishing: 60] [Article Influence: 9.3] [Reference Citation Analysis]
221 Xu X, Tao Y, Shan L, Chen R, Jiang H, Qian Z, Cai F, Ma L, Yu Y. The Role of MicroRNAs in Hepatocellular Carcinoma. J Cancer 2018;9:3557-69. [PMID: 30310513 DOI: 10.7150/jca.26350] [Cited by in Crossref: 57] [Cited by in F6Publishing: 64] [Article Influence: 14.3] [Reference Citation Analysis]
222 Li J, Xu Y, Long X, Wang W, Jiao H, Mei Z, Yin Q, Ma L, Zhou A, Wang L, Yao M, Xia Q, Chen G. Cbx4 Governs HIF-1α to Potentiate Angiogenesis of Hepatocellular Carcinoma by Its SUMO E3 Ligase Activity. Cancer Cell 2014;25:118-31. [DOI: 10.1016/j.ccr.2013.12.008] [Cited by in Crossref: 110] [Cited by in F6Publishing: 118] [Article Influence: 13.8] [Reference Citation Analysis]
223 Reiberger T, Chen Y, Ramjiawan RR, Hato T, Fan C, Samuel R, Roberge S, Huang P, Lauwers GY, Zhu AX. An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis. Nat Protoc. 2015;10:1264-1274. [PMID: 26203823 DOI: 10.1038/nprot.2015.080] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 7.9] [Reference Citation Analysis]
224 Fodor D, Jung I, Turdean S, Satala C, Gurzu S. Angiogenesis of hepatocellular carcinoma: An immunohistochemistry study. World J Hepatol 2019; 11(3): 294-304 [PMID: 30967907 DOI: 10.4254/wjh.v11.i3.294] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
225 Peng S, Ding H, Fu T, Wang B, Wang W, Zhou J. Savitzky-Golay filter based contrast-enhanced ultrasound quantification in hepatic tumors: Methodology and its correlation with tumor angiogenesis. CH 2019;73:271-82. [DOI: 10.3233/ch-180432] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
226 Shan R, Wang B, Wang A, Sun Z, Dong F, Liu J, Sun H. Endoglin-targeted contrast-enhanced ultrasound imaging in hepatoblastoma xenografts. Oncol Lett 2018;16:3784-90. [PMID: 30127989 DOI: 10.3892/ol.2018.9067] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
227 Chen J, White SB, Harris KR, Li W, Yap JW, Kim DH, Lewandowski RJ, Shea LD, Larson AC. Poly(lactide-co-glycolide) microspheres for MRI-monitored delivery of sorafenib in a rabbit VX2 model. Biomaterials 2015;61:299-306. [PMID: 26022791 DOI: 10.1016/j.biomaterials.2015.05.010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
228 Idée JM, Guiu B. Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review. Crit Rev Oncol Hematol. 2013;88:530-549. [PMID: 23921081 DOI: 10.1016/j.critrevonc.2013.07.003] [Cited by in Crossref: 107] [Cited by in F6Publishing: 93] [Article Influence: 11.9] [Reference Citation Analysis]
229 Yang SH, Lin J, Lu F, Dai YY, Han ZH, Fu CX, Hu FL, Gu HC. Contrast-enhanced susceptibility weighted imaging with ultrasmall superparamagnetic iron oxide improves the detection of tumor vascularity in a hepatocellular carcinoma nude mouse model. J Magn Reson Imaging 2016;44:288-95. [PMID: 26808392 DOI: 10.1002/jmri.25167] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
230 Kim SM, Han JM, Le TT, Sohng JK, Jung HJ. Anticancer and Antiangiogenic Activities of Novel α-Mangostin Glycosides in Human Hepatocellular Carcinoma Cells via Downregulation of c-Met and HIF-1α. Int J Mol Sci 2020;21:E4043. [PMID: 32516967 DOI: 10.3390/ijms21114043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
231 Akiyama Y, Kimura Y, Enatsu R, Mikami T, Wanibuchi M, Mikuni N. Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience. World Neurosurg 2018;113:e508-14. [PMID: 29476996 DOI: 10.1016/j.wneu.2018.02.070] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
232 Marcu LG, Forster JC, Bezak E. The Potential Role of Radiomics and Radiogenomics in Patient Stratification by Tumor Hypoxia Status. J Am Coll Radiol 2019;16:1329-37. [PMID: 31492411 DOI: 10.1016/j.jacr.2019.05.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
233 Chau I, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Kudo M, Pfiffer T, Hatano E, Chung HC, Kopeckova K, Phelip JM, Brandi G, Ohkawa S, Li CP, Okusaka T, Hsu Y, Abada PB, Zhu AX. Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study. Br J Cancer 2018;119:19-26. [PMID: 29808014 DOI: 10.1038/s41416-018-0103-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
234 Muto J, Shirabe K, Sugimachi K, Maehara Y. Review of angiogenesis in hepatocellular carcinoma. Hepatol Res. 2015;45:1-9. [PMID: 24533487 DOI: 10.1111/hepr.12310] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 5.5] [Reference Citation Analysis]
235 Bertino G, Demma S, Ardiri A, Proiti M, Gruttadauria S, Toro A, Malaguarnera G, Bertino N, Malaguarnera M, Malaguarnera M. Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. Biomed Res Int. 2014;2014:203693. [PMID: 25089265 DOI: 10.1155/2014/203693] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 5.9] [Reference Citation Analysis]
236 Pardee AD, Butterfield LH. Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. Oncoimmunology 2012;1:48-55. [PMID: 22720211 DOI: 10.4161/onci.1.1.18344] [Cited by in Crossref: 107] [Cited by in F6Publishing: 104] [Article Influence: 107.0] [Reference Citation Analysis]
237 Yu S, Jing L, Yin XR, Wang MC, Chen YM, Guo Y, Nan KJ, Han LL. MiR-195 suppresses the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by inhibiting YAP. Oncotarget 2017;8:99757-71. [PMID: 29245938 DOI: 10.18632/oncotarget.20909] [Cited by in Crossref: 25] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
238 Liu C, Chern G, Hsu F, Huang K, Sung Y, Huang H, Qiu JT, Wang S, Lin C, Wu C, Wu H, Liu J, Chen Y. A multifunctional nanocarrier for efficient TRAIL-based gene therapy against hepatocellular carcinoma with desmoplasia in mice: Liu, Chern, et al. Hepatology 2018;67:899-913. [DOI: 10.1002/hep.29513] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
239 Kanzaki H, Chiba T, Ao J, Koroki K, Kanayama K, Maruta S, Maeda T, Kusakabe Y, Kobayashi K, Kanogawa N, Kiyono S, Nakamura M, Kondo T, Saito T, Nakagawa R, Ogasawara S, Suzuki E, Ooka Y, Muroyama R, Nakamoto S, Yasui S, Tawada A, Arai M, Kanda T, Maruyama H, Mimura N, Kato J, Zen Y, Ohtsuka M, Iwama A, Kato N. The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma. Sci Rep 2021;11:5303. [PMID: 33674622 DOI: 10.1038/s41598-021-84117-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
240 Orlacchio A, Chegai F, Francioso S, Merolla S, Monti S, Angelico M, Tisone G, Mannelli L. Repeated Transarterial Chemoembolization with Degradable Starch 
Microspheres (DSMs-TACE) of Unresectable Hepatocellular Carcinoma: A Prospective Pilot Study. Curr Med Imaging Rev 2018;14:637-45. [PMID: 30197583 DOI: 10.2174/1573405613666170616123657] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
241 Ali MM, H Borai I, Ghanem HM, H Abdel-Halim A, Mousa FM. The prophylactic and therapeutic effects of Momordica charantia methanol extract through controlling different hallmarks of the hepatocarcinogenesis. Biomed Pharmacother 2018;98:491-8. [PMID: 29287196 DOI: 10.1016/j.biopha.2017.12.096] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
242 Zhou X, Shi M, Cao J, Yuan T, Yu G, Chen Y, Fang W, Li H. S100 Calcium Binding Protein A10, A Novel Oncogene, Promotes the Proliferation, Invasion, and Migration of Hepatocellular Carcinoma. Front Genet 2021;12:695036. [PMID: 34178044 DOI: 10.3389/fgene.2021.695036] [Reference Citation Analysis]
243 Schietroma I, Scheri GC, Pinacchio C, Statzu M, Petruzziello A, Vullo V. Hepatitis C Virus and Hepatocellular Carcinoma: Pathogenetic Mechanisms and Impact of Direct-Acting Antivirals. Open Virol J. 2018;12:16-25. [PMID: 29541275 DOI: 10.2174/1874357901812010016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
244 Zhang N, Wang LR, Li DD, Ma DN, Wang CH, He XG, Gao DM, Wang L, Tang ZY. Interferon-α Combined With Herbal Compound "Songyou Yin" Effectively Inhibits the Increased Invasiveness and Metastasis by Insufficient Radiofrequency Ablation of Hepatocellular Carcinoma in an Animal Model. Integr Cancer Ther 2018;17:1260-9. [PMID: 30234394 DOI: 10.1177/1534735418801525] [Reference Citation Analysis]
245 Gao J, Rong Y, Huang Y, Shi P, Wang X, Meng X, Dong J, Wu C. Cirrhotic stiffness affects the migration of hepatocellular carcinoma cells and induces sorafenib resistance through YAP. J Cell Physiol. 2019;234:2639-2648. [PMID: 30145835 DOI: 10.1002/jcp.27078] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
246 Lu M, Wu J, He F, Wang XL, Li C, Chen ZN, Bian H. Cell expression patterns of CD147 in N-diethylnitrosamine/phenobarbital-induced mouse hepatocellular carcinoma. J Mol Histol 2015;46:79-91. [PMID: 25447507 DOI: 10.1007/s10735-014-9602-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
247 Pinter M, Sieghart W, Schmid M, Dauser B, Prager G, Dienes HP, Trauner M, Peck-Radosavljevic M. Hedgehog inhibition reduces angiogenesis by downregulation of tumoral VEGF-A expression in hepatocellular carcinoma. United European Gastroenterol J 2013;1:265-75. [PMID: 24917971 DOI: 10.1177/2050640613496605] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
248 Kasprzak A, Adamek A. Role of Endoglin (CD105) in the Progression of Hepatocellular Carcinoma and Anti-Angiogenic Therapy. Int J Mol Sci. 2018;19. [PMID: 30563158 DOI: 10.3390/ijms19123887] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
249 Chen G, Nakamura I, Dhanasekaran R, Iguchi E, Tolosa EJ, Romecin PA, Vera RE, Almada LL, Miamen AG, Chaiteerakij R, Zhou M, Asiedu MK, Moser CD, Han S, Hu C, Banini BA, Oseini AM, Chen Y, Fang Y, Yang D, Shaleh HM, Wang S, Wu D, Song T, Lee JS, Thorgeirsson SS, Chevet E, Shah VH, Fernandez-Zapico ME, Roberts LR. Transcriptional Induction of Periostin by a Sulfatase 2-TGFβ1-SMAD Signaling Axis Mediates Tumor Angiogenesis in Hepatocellular Carcinoma. Cancer Res 2017;77:632-45. [PMID: 27872089 DOI: 10.1158/0008-5472.CAN-15-2556] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
250 Chegai F, Orlacchio A, Merolla S, Monti S, Mannelli L. Intermediate hepatocellular carcinoma: the role of transarterial therapy. Hepat Oncol 2015;2:399-408. [PMID: 26998220 DOI: 10.2217/hep.15.32] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
251 Huang Z, Zhou JK, Peng Y, He W, Huang C. The role of long noncoding RNAs in hepatocellular carcinoma. Mol Cancer 2020;19:77. [PMID: 32295598 DOI: 10.1186/s12943-020-01188-4] [Cited by in Crossref: 62] [Cited by in F6Publishing: 73] [Article Influence: 31.0] [Reference Citation Analysis]
252 Hack SP, Zhu AX, Wang Y. Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities. Front Immunol 2020;11:598877. [PMID: 33250900 DOI: 10.3389/fimmu.2020.598877] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
253 Duda DG, Dima SO, Cucu D, Sorop A, Klein S, Ancukiewicz M, Kitahara S, Iacob S, Bacalbasa N, Tomescu D, Herlea V, Tanase C, Croitoru A, Popescu I. Potential Circulating Biomarkers of Recurrence after Hepatic Resection or Liver Transplantation in Hepatocellular Carcinoma Patients. Cancers (Basel) 2020;12:E1275. [PMID: 32443546 DOI: 10.3390/cancers12051275] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
254 Wengert GJ, Bickel H, Breitenseher J, Ba-Ssalamah A. [Primary liver tumors : hepatocellular versus intrahepatic cholangiocellular carcinoma]. Radiologe 2015;55:27-35. [PMID: 25575724 DOI: 10.1007/s00117-014-2705-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
255 Cho E, Kim HC, Lee JH, Jeong-Ju Yoo WM, Cho YY, Lee MJ, Cho Y, Lee DH, Lee YB, Yu SJ. Serum insulin-like growth factor-1 predicts disease progression and survival in patients with hepatocellular carcinoma who undergo transarterial chemoembolization. PLoS One. 2014;9:e90862. [PMID: 24595361 DOI: 10.1371/journal.pone.0090862] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
256 Sun HJ, Wu ZY, Nie XW, Wang XY, Bian JS. Implications of hydrogen sulfide in liver pathophysiology: Mechanistic insights and therapeutic potential. J Adv Res 2021;27:127-35. [PMID: 33318872 DOI: 10.1016/j.jare.2020.05.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
257 Hato T, Zhu AX, Duda DG. Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma. Immunotherapy 2016;8:299-313. [PMID: 26865127 DOI: 10.2217/imt.15.126] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 11.3] [Reference Citation Analysis]
258 Ramadan HK, Meghezel EM, Abdel-Malek MO, Askar AA, Hetta HF, Mahmoud AA, Abdel-Aal AM. Correlation Between Vascular Endothelial Growth Factor and Long-Term Occurrence of HCV-Related Hepatocellular Carcinoma After Treatment with Direct-Acting Antivirals. Cancer Invest 2021;39:653-60. [PMID: 34224250 DOI: 10.1080/07357907.2021.1951751] [Reference Citation Analysis]
259 Chen P, Duan X, Li X, Li J, Ba Q, Wang H. HIPK2 suppresses tumor growth and progression of hepatocellular carcinoma through promoting the degradation of HIF-1α. Oncogene 2020;39:2863-76. [PMID: 32034309 DOI: 10.1038/s41388-020-1190-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
260 Pinter M, Jain RK, Duda DG. The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review. JAMA Oncol 2021;7:113-23. [PMID: 33090190 DOI: 10.1001/jamaoncol.2020.3381] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 34.0] [Reference Citation Analysis]
261 Patel J, Jain B, Singh AK, Susan MABH, Jean-paul L. Mn-Doped ZnS Quantum dots–An Effective Nanoscale Sensor. Microchemical Journal 2020;155:104755. [DOI: 10.1016/j.microc.2020.104755] [Cited by in Crossref: 14] [Article Influence: 7.0] [Reference Citation Analysis]
262 Qin S, Li Q, Gu S, Chen X, Lin L, Wang Z, Xu A, Chen X, Zhou C, Ren Z, Yang L, Xu L, Bai Y, Chen L, Li J, Pan H, Cao B, Fang W, Wu W, Wang G, Cheng Y, Yu Z, Zhu X, Jiang D, Lu Y, Wang H, Xu J, Bai L, Liu Y, Lin H, Wu C, Zhang Y, Yan P, Jin C, Zou J. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol 2021;6:559-68. [PMID: 33971141 DOI: 10.1016/S2468-1253(21)00109-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
263 Li X, Li J, Li C, Guo Q, Wu M, Su L, Dou Y, Wu X, Xiao Z, Zhang X. Aminopeptidase N-targeting nanomolecule-assisted delivery of VEGF siRNA to potentiate antitumour therapy by suppressing tumour revascularization and enhancing radiation response. J Mater Chem B 2021;9:7530-43. [PMID: 34551051 DOI: 10.1039/d1tb00990g] [Reference Citation Analysis]
264 Delgado E, Bahal R, Yang J, Lee JM, Ly DH, Monga SP. β-Catenin knockdown in liver tumor cells by a cell permeable gamma guanidine-based peptide nucleic acid. Curr Cancer Drug Targets. 2013;13:867-878. [PMID: 23822752 DOI: 10.2174/15680096113139990081] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
265 Wang Y, Song F, Zhang X, Yang C, Zhang J. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma. Oxidative Medicine and Cellular Longevity 2022;2022:1-28. [DOI: 10.1155/2022/1592905] [Reference Citation Analysis]
266 Pancoska P, Carr BI. Macro- and micro-environmental factors in clinical hepatocellular cancer. Semin Oncol 2014;41:185-94. [PMID: 24787292 DOI: 10.1053/j.seminoncol.2014.03.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
267 Giovannini C, Baglioni M, Baron Toaldo M, Ventrucci C, D'Adamo S, Cipone M, Chieco P, Gramantieri L, Bolondi L. Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma. Oncotarget 2013;4:1618-31. [PMID: 24113128 DOI: 10.18632/oncotarget.1221] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
268 Vitale G, Gitto S, Campani C, Turco L, Baldan A, Marra F, Morelli MC. Biological therapies in patients with liver disease: are they really lifesavers? Expert Opin Biol Ther 2021;:1-18. [PMID: 34860629 DOI: 10.1080/14712598.2022.2013799] [Reference Citation Analysis]
269 Elghandour AM, Bayoumy EM, Ibrahim WA, Sayed MM, Salama AB, Teama NM, Salama MM. Vascular endothelial growth factor in relation to the development of hepatocellular carcinoma in hepatitis C virus patients treated by direct-acting antivirals. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-020-00073-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
270 Ku CY, Liu YH, Lin HY, Lu SC, Lin JY. Liver fatty acid-binding protein (L-FABP) promotes cellular angiogenesis and migration in hepatocellular carcinoma. Oncotarget 2016;7:18229-46. [PMID: 26919097 DOI: 10.18632/oncotarget.7571] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
271 Wang Y, Liu D, Zhang T, Xia L. FGF/FGFR Signaling in Hepatocellular Carcinoma: From Carcinogenesis to Recent Therapeutic Intervention. Cancers (Basel) 2021;13:1360. [PMID: 33802841 DOI: 10.3390/cancers13061360] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
272 Zhang NB, Zhang JX. Advances in research of tumor microenvironment in hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2014; 22(31): 4774-4784 [DOI: 10.11569/wcjd.v22.i31.4774] [Reference Citation Analysis]
273 Ye ZL, Huang Y, Li LF, Zhu HL, Gao HX, Liu H, Lv SQ, Xu ZH, Zheng LN, Liu T, Zhang JL, Jin HJ, Qian QJ. Argonaute 2 promotes angiogenesis via the PTEN/VEGF signaling pathway in human hepatocellular carcinoma. Acta Pharmacol Sin 2015;36:1237-45. [PMID: 25937637 DOI: 10.1038/aps.2015.18] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
274 Adachi Y, Matsuki M, Watanabe H, Takase K, Kodama K, Matsui J, Funahashi Y, Nomoto K. Antitumor and Antiangiogenic Activities of Lenvatinib in Mouse Xenograft Models of Vascular Endothelial Growth Factor-Induced Hypervascular Human Hepatocellular Carcinoma. Cancer Invest 2019;37:185-98. [PMID: 31006280 DOI: 10.1080/07357907.2019.1601209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
275 Jin PR, Ta YN, Chen IT, Yu YN, Hsieh HT, Nguyen VT, Hsieh SY, Hsia T, Liu H, Hsu CW, Han JL, Chen Y. Cinchona Alkaloid-Inspired Urea-Containing Autophagy Inhibitor Shows Single-Agent Anticancer Efficacy. J Med Chem 2021;64:14513-25. [PMID: 34558909 DOI: 10.1021/acs.jmedchem.1c01036] [Reference Citation Analysis]
276 Xing S, Zhang B, Hua R, Tai WC, Zeng Z, Xie B, Huang C, Xue J, Xiong S, Yang J, Liu S, Li H. URG4/URGCP enhances the angiogenic capacity of human hepatocellular carcinoma cells in vitro via activation of the NF-κB signaling pathway. BMC Cancer 2015;15:368. [PMID: 25947641 DOI: 10.1186/s12885-015-1378-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
277 Kuo ZK, Lin MW, Lu IH, Yao HJ, Wu HC, Wang CC, Lin SH, Wu SY, Tong TS, Cheng YC, Yen JH, Ko CH, Chiou SJ, Pan IH, Tseng HW. Antiangiogenic and antihepatocellular carcinoma activities of the Juniperus chinensis extract. BMC Complement Altern Med 2016;16:277. [PMID: 27502492 DOI: 10.1186/s12906-016-1250-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
278 Roviello G, Sohbani N, Petrioli R, Rodriquenz MG. Ramucirumab as a second line therapy for advanced HCC: a significant achievement or a wasted opportunity for personalised therapy? Invest New Drugs 2019;37:1274-88. [PMID: 30879152 DOI: 10.1007/s10637-019-00760-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
279 Kim TH, Woo S, Han S, Suh CH, Do RKG, Lee JM. Risk Factors for Hypervascularization in Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement: A Systematic Review and Meta-analysis. Acad Radiol 2020:S1076-6332(20)30512-2. [PMID: 32962925 DOI: 10.1016/j.acra.2020.08.031] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
280 Wei T, Zhang LN, Lv Y, Ma XY, Zhi L, Liu C, Ma F, Zhang XF. Overexpression of platelet-derived growth factor receptor alpha promotes tumor progression and indicates poor prognosis in hepatocellular carcinoma. Oncotarget. 2014;5:10307-10317. [PMID: 25333264 DOI: 10.18632/oncotarget.2537] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
281 Gong C, Fang J, Li G, Liu HH, Liu ZS. Effects of microRNA-126 on cell proliferation, apoptosis and tumor angiogenesis via the down-regulating ERK signaling pathway by targeting EGFL7 in hepatocellular carcinoma. Oncotarget 2017;8:52527-42. [PMID: 28881749 DOI: 10.18632/oncotarget.17283] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
282 Khan MGM, Ghosh A, Variya B, Santharam MA, Ihsan AU, Ramanathan S, Ilangumaran S. Prognostic significance of SOCS1 and SOCS3 tumor suppressors and oncogenic signaling pathway genes in hepatocellular carcinoma. BMC Cancer 2020;20:774. [PMID: 32807134 DOI: 10.1186/s12885-020-07285-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
283 Li XP, Cui DL. Role of tumor microenvironment in hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2014; 22(9): 1219-1225 [DOI: 10.11569/wcjd.v22.i9.1219] [Reference Citation Analysis]
284 Chan SL, Yeo W. Targeted therapy of hepatocellular carcinoma: Present and future: Novel treatment for liver cancer. Journal of Gastroenterology and Hepatology 2012;27:862-72. [DOI: 10.1111/j.1440-1746.2012.07096.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 5.6] [Reference Citation Analysis]
285 Ye G, Qin Y, Lu X, Xu X, Xu S, Wu C, Wang X, Wang S, Pan D. The association of renin-angiotensin system genes with the progression of hepatocellular carcinoma. Biochem Biophys Res Commun 2015;459:18-23. [PMID: 25701390 DOI: 10.1016/j.bbrc.2015.02.030] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
286 Piccioni F, Fiore E, Bayo J, Atorrasagasti C, Peixoto E, Rizzo M, Malvicini M, Tirado-González I, García MG, Alaniz L, Mazzolini G. 4-methylumbelliferone inhibits hepatocellular carcinoma growth by decreasing IL-6 production and angiogenesis. Glycobiology 2015;25:825-35. [PMID: 25882295 DOI: 10.1093/glycob/cwv023] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.6] [Reference Citation Analysis]
287 Ponziani FR, Nicoletti A, Gasbarrini A, Pompili M. Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma. Ther Adv Med Oncol. 2019;11:1758835919848184. [PMID: 31205505 DOI: 10.1177/1758835919848184] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
288 Kudo M, Hatano E, Ohkawa S, Fujii H, Masumoto A, Furuse J, Wada Y, Ishii H, Obi S, Kaneko S, Kawazoe S, Yokosuka O, Ikeda M, Ukai K, Morita S, Tsuji A, Kudo T, Shimada M, Osaki Y, Tateishi R, Sugiyama G, Abada PB, Yang L, Okusaka T, Zhu AX. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial. J Gastroenterol. 2017;52:494-503. [PMID: 27549242 DOI: 10.1007/s00535-016-1247-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
289 Soule E, Lamsal S, Lall C, Matteo J. Eye Opener to EtOH Ablation for Juxta-Cardiac Hepatocellular Carcinoma. Gastrointest Tumors 2019;5:109-16. [PMID: 30976582 DOI: 10.1159/000495135] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
290 Metwaly HA, El-Gayar AM, El-Shishtawy MM. Inhibition of the signaling pathway of syndecan-1 by synstatin: A promising anti-integrin inhibitor of angiogenesis and proliferation in HCC in rats. Arch Biochem Biophys 2018;652:50-8. [PMID: 29928859 DOI: 10.1016/j.abb.2018.06.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
291 Yang YL, Chang YH, Li CJ, Huang YH, Tsai MC, Chu PY, Lin HY. New Insights into the Role of miR-29a in Hepatocellular Carcinoma: Implications in Mechanisms and Theragnostics. J Pers Med 2021;11:219. [PMID: 33803804 DOI: 10.3390/jpm11030219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
292 Chen Y, Li L, Qian X, Ge Y, Xu G. High expression of TRIM11 correlates with poor prognosis in patients with hepatocellular carcinoma. Clin Res Hepatol Gastroenterol 2017;41:190-6. [PMID: 28065743 DOI: 10.1016/j.clinre.2016.09.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
293 Wang X, Zhang Y, Feng T, Su G, He J, Gao W, Shen Y, Liu X. Fluid Shear Stress Promotes Autophagy in Hepatocellular Carcinoma Cells. Int J Biol Sci 2018;14:1277-90. [PMID: 30123076 DOI: 10.7150/ijbs.27055] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
294 Santhekadur PK, Das SK, Gredler R, Chen D, Srivastava J, Robertson C, Baldwin AS, Fisher PB, Sarkar D. Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor κB and miR-221. J Biol Chem. 2012;287:13952-13958. [PMID: 22396537 DOI: 10.1074/jbc.m111.321646] [Cited by in Crossref: 91] [Cited by in F6Publishing: 62] [Article Influence: 9.1] [Reference Citation Analysis]
295 Zhang H, Liu R, Sun L, Guo W, Hu X. The Effect of Ferroptosis-Related Genes on Prognosis and Tumor Mutational Burden in Hepatocellular Carcinoma. J Oncol 2021;2021:7391560. [PMID: 34457006 DOI: 10.1155/2021/7391560] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
296 Aoki S, Cobbold M, Zhu AX, Duda DG. Can smart nanomedicine deliver effective targeted cytotoxic treatments to hepatocellular carcinomas while reducing the liver damage? Hepatology 2018;67:826-8. [PMID: 29077214 DOI: 10.1002/hep.29617] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
297 Chen M, Zhou X, Chen R, Wang J, Ye RD, Wang Y, Wu C, Mahato RI. Nano-carriers for delivery and targeting of active ingredients of Chinese medicine for hepatocellular carcinoma therapy. Materials Today 2019;25:66-87. [DOI: 10.1016/j.mattod.2018.10.040] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
298 Ippolito D, Querques G, Okolicsanyi S, Talei Franzesi C, Pecorelli A, Lombardi S, Orsini E, Strazzabosco M, Sironi S. Dynamic contrast enhanced perfusion CT imaging: A diagnostic biomarker tool for survival prediction of tumour response to antiangiogenetic treatment in patients with advanced HCC lesions. Eur J Radiol 2018;106:62-8. [PMID: 30150052 DOI: 10.1016/j.ejrad.2018.07.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
299 Lee SJ, Lim HY. Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists. Expert Opinion on Emerging Drugs 2017;22:191-200. [DOI: 10.1080/14728214.2017.1330886] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
300 Nakao K, Tanaka S, Miura T, Sato K, Matsumura S, Aihara A, Mitsunori Y, Ban D, Ochiai T, Kudo A, Arii S, Tanabe M. Novel Aurora/vascular endothelial growth factor receptor dual kinase inhibitor as treatment for hepatocellular carcinoma. Cancer Sci 2015;106:1016-22. [PMID: 26011703 DOI: 10.1111/cas.12701] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
301 Bazzazi H, Popel AS. Computational investigation of sphingosine kinase 1 (SphK1) and calcium dependent ERK1/2 activation downstream of VEGFR2 in endothelial cells. PLoS Comput Biol 2017;13:e1005332. [PMID: 28178265 DOI: 10.1371/journal.pcbi.1005332] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
302 Jain RK, Chauhan VP, Duda DG. Vascular and Interstitial Biology of Tumors. Abeloff's Clinical Oncology. Elsevier; 2014. pp. 108-126.e5. [DOI: 10.1016/b978-1-4557-2865-7.00008-4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
303 Kimura K, Nakayama M, Naito I, Komiyama T, Ichimura K, Asano H, Tsukuda K, Ohtsuka A, Oohashi T, Miyoshi S, Ninomiya Y. Human collagen XV is a prominent histopathological component of sinusoidal capillarization in hepatocellular carcinogenesis. Int J Clin Oncol 2016;21:302-9. [DOI: 10.1007/s10147-015-0888-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
304 Zhu AX, Ancukiewicz M, Supko JG, Sahani DV, Blaszkowsky LS, Meyerhardt JA, Abrams TA, McCleary NJ, Bhargava P, Muzikansky A. Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. Clin Cancer Res. 2013;19:1557-1566. [PMID: 23362324 DOI: 10.1158/1078-0432.ccr-12-3041] [Cited by in Crossref: 50] [Cited by in F6Publishing: 29] [Article Influence: 5.6] [Reference Citation Analysis]
305 Sung YC, Jin PR, Chu LA, Hsu FF, Wang MR, Chang CC, Chiou SJ, Qiu JT, Gao DY, Lin CC, Chen YS, Hsu YC, Wang J, Wang FN, Yu PL, Chiang AS, Wu AY, Ko JJ, Lai CP, Lu TT, Chen Y. Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies. Nat Nanotechnol 2019;14:1160-9. [PMID: 31740794 DOI: 10.1038/s41565-019-0570-3] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 23.0] [Reference Citation Analysis]
306 Dai B, Shi X, Ma N, Ma W, Zhang Y, Yang T, Zhang J, He L. HMQ-T-B10 induces human liver cell apoptosis by competitively targeting EphrinB2 and regulating its pathway. J Cell Mol Med 2018;22:5231-43. [PMID: 30589500 DOI: 10.1111/jcmm.13729] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
307 Su YC, Lin IH, Siao YM, Liu CJ, Yeh CC. Modulation of the Tumor Metastatic Microenvironment and Multiple Signal Pathways by Prunella vulgaris in Human Hepatocellular Carcinoma. Am J Chin Med 2016;44:835-49. [PMID: 27222069 DOI: 10.1142/S0192415X16500464] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
308 Zhu B, Lin N, Zhang M, Zhu Y, Cheng H, Chen S, Ling Y, Pan W, Xu R. Activated hepatic stellate cells promote angiogenesis via interleukin-8 in hepatocellular carcinoma. J Transl Med. 2015;13:365. [PMID: 26593962 DOI: 10.1186/s12967-015-0730-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
309 Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol 2015;12:408-24. [PMID: 26054909 DOI: 10.1038/nrclinonc.2015.103] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
310 Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011;10:417-27. [PMID: 21629292 DOI: 10.1038/nrd3455] [Cited by in Crossref: 985] [Cited by in F6Publishing: 912] [Article Influence: 89.5] [Reference Citation Analysis]
311 Maestri M, Pallozzi M, Santopaolo F, Cerrito L, Pompili M, Gasbarrini A, Ponziani FR. Durvalumab: an investigational agent for unresectable hepatocellular carcinoma. Expert Opinion on Investigational Drugs. [DOI: 10.1080/13543784.2022.2033208] [Reference Citation Analysis]
312 Daoudaki M, Fouzas I. Hepatocellular carcinoma. Wien Med Wochenschr 2014;164:450-5. [PMID: 25182146 DOI: 10.1007/s10354-014-0296-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
313 Chatziioannou AN, Siskos AP, Loxas D, Kavatzas N, Agrogiannis G, Fokas D, Malagari K, Kostomitsopoulos NG, Tsigkou O, Tamvakopoulos C. Transarterial embolization with sorafenib in animal livers: a pharmacokinetics study. J Vasc Interv Radiol 2013;24:1657-63.e1. [PMID: 24060438 DOI: 10.1016/j.jvir.2013.08.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
314 Liu XN, Yuan JH, Wang TT, Pan W, Sun SH. An alternative POLDIP3 transcript promotes hepatocellular carcinoma progression. Biomed Pharmacother 2017;89:276-83. [PMID: 28236701 DOI: 10.1016/j.biopha.2017.01.139] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
315 Lin N, Meng L, Lin J, Chen S, Zhang P, Chen Q, Lin Y. Activated hepatic stellate cells promote angiogenesis in hepatocellular carcinoma by secreting angiopoietin-1. J Cell Biochem 2020;121:1441-51. [PMID: 31609020 DOI: 10.1002/jcb.29380] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
316 Guo XL, Li D, Sun K, Wang J, Liu Y, Song JR, Zhao QD, Zhang SS, Deng WJ, Zhao X, Wu MC, Wei LX. Inhibition of autophagy enhances anticancer effects of bevacizumab in hepatocarcinoma. J Mol Med (Berl). 2013;91:473-483. [PMID: 23052483 DOI: 10.1007/s00109-012-0966-0] [Cited by in Crossref: 71] [Cited by in F6Publishing: 73] [Article Influence: 7.1] [Reference Citation Analysis]
317 Bergmann J, Müller M, Baumann N, Reichert M, Heneweer C, Bolik J, Lücke K, Gruber S, Carambia A, Boretius S, Leuschner I, Becker T, Rabe B, Herkel J, Wunderlich FT, Mittrücker HW, Rose-John S, Schmidt-Arras D. IL-6 trans-signaling is essential for the development of hepatocellular carcinoma in mice. Hepatology 2017;65:89-103. [PMID: 27770462 DOI: 10.1002/hep.28874] [Cited by in Crossref: 71] [Cited by in F6Publishing: 73] [Article Influence: 11.8] [Reference Citation Analysis]
318 Dai Y, Cui J, Gan P, Li W. Downregulation of tetrahydrobiopterin inhibits tumor angiogenesis in BALB/c-nu mice with hepatocellular carcinoma. Oncol Rep 2016;36:669-75. [PMID: 27279530 DOI: 10.3892/or.2016.4850] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]